




02029090

PerkinElmer Annual Report 2001

*Arts*  
*P.E*  
*12/31/01*

REC'D C.I.C.  
APR 2 2002  
071






PROCESSED

APR 08 2002



THOMSON  
FINANCIAL



PerkinElmer™  
precisely.

	LIFE SCIENCES	ANALYTICAL INSTRUMENTS	OPTOELECTRONICS
			
% 2002 Estimated Revenues (US \$1.4 billion)	40%	35%	25%
% 2002 Estimated Revenue By Market	<ul style="list-style-type: none"> <li>Drug Discovery 80%</li> <li>Genetic Disease Screening 20%</li> <li>100%</li> </ul>	<ul style="list-style-type: none"> <li>Pharmaceutical 30%</li> <li>Environmental 20%</li> <li>General Analytical 50%</li> <li>100%</li> </ul>	<ul style="list-style-type: none"> <li>Biomedical 25%</li> <li>Telecom 10%</li> <li>Industrial 65%</li> <li>100%</li> </ul>
% 2002 Estimated Revenue By Geography	<ul style="list-style-type: none"> <li>Americas 55%</li> <li>Europe 35%</li> <li>Rest of World 10%</li> <li>100%</li> </ul>	<ul style="list-style-type: none"> <li>Americas 40%</li> <li>Europe 40%</li> <li>Rest of World 20%</li> <li>100%</li> </ul>	<ul style="list-style-type: none"> <li>Americas 60%</li> <li>Europe 25%</li> <li>Rest of World 15%</li> <li>100%</li> </ul>
Product/Service Focus	Drug discovery, research, and clinical screening products, services and technologies for the life sciences industry. Offers a complete line of instrumentation, reagents and consumables, as well as assay development, sample preparation and biochip technologies for drug discovery and genetic disease screening.	Analytical instrumentation, informatics and services used to accelerate the drug development and manufacturing process, decipher molecular mechanisms of drug actions, monitor and test for environmental pollutants, confirm nutritional content and safety of foods and beverages, and analyze the purity of raw materials used in the development of semiconductor and optical products.	Provides a broad spectrum of optoelectronic products, including large area amorphous silicon detectors, fiber optic test equipment, telecommunications components, high-performance specialty lighting sources and advanced sensing and imaging technologies.
Market Presence	#1 in drug screening; #1 in liquid handling and sample prep; #1 in genetic disease screening. Customers include pharmaceutical and biotechnology firms, academic institutions and government health agencies.	Leader in the pharmaceutical quality assurance testing and environmental markets. Provides application-specific solutions for the chemical, food and beverage, and general analytical industries.	Leading positions in digital imaging and medical sensors. End markets include the biomedical, telecommunications and industrial segments.
Representative Products	<ul style="list-style-type: none"> <li>EnVision™ modular multilabel plate reader</li> <li>ViewLux™ ultra-HTS plate imager</li> <li>VICTOR™2 multilabel plate reader</li> <li>MiniTrak™ high-throughput automation system</li> <li>MultiPROBE® II sample processing system</li> <li>ImageTrak™ automated liquid handling and imaging system</li> <li>UltraVIEW™ high-resolution, live cell confocal imaging system</li> <li>AutoDELPHIA™ neonatal screening system</li> </ul>	<ul style="list-style-type: none"> <li>Spectrum™ Spotlight FTIR imaging system</li> <li>Elan® DRC-110CP/MS</li> <li>LABWORKS™ laboratory information management system (LIMS)</li> <li>TurboMass™ Gold GC/MS</li> <li>Assured™ QA/QC system</li> </ul>	<ul style="list-style-type: none"> <li>Amorphous silicon (aSi), flat panel digital imaging technology</li> <li>ProForm® Metro laser direct CTP imaging technology</li> <li>CHROMOS1.1™ portable chromatic dispersion measurement set</li> <li>2.5 and 10-Gbps receiver offerings</li> <li>SPCM (Single Photon Counting Module)</li> <li>Cermax® lamps, which include an integral elliptical reflector for a focused output</li> </ul>

PerkinElmer, Inc. is a global technology leader focused in three businesses – Life Sciences, Analytical Instruments and Optoelectronics. Combining operational excellence and technology expertise, PerkinElmer creates innovative solutions for customers in health sciences, communications and other markets whose applications demand precision and speed. The company operates in more than 125 countries, and is a component of the S&P 500 Index.



# Dear Fellow Shareholder,

2001 was another year of excellent progress in our journey to become a world-class, global, high-technology leader. Despite a very soft economic environment, we grew our earnings per share by 18%, marking our fourth consecutive year of double-digit earnings growth. Our operating margins expanded to 14%, up 200 basis points, and cash flow grew 19% over last year. Even more important for our future outlook, we shifted our portfolio of businesses to a higher growth health sciences focus through several key acquisitions and divestitures.

With the stock market under pressure, our return in 2001 was disappointing at -31%, even though we outperformed sector peers. However, our shareholder return since we started the transformation of PerkinElmer (then EG&G) in January 1998, is an impressive 39% average annual return through December 2001, dramatically outperforming all the major indices.

We are proud of our 2001 progress. It has given us strong momentum for 2002, as we continue to build a world-class operating company and a higher growth business portfolio.

## **Building a world-class operating company**

At no time in PerkinElmer's history was the value of our efforts to build world-class operations more apparent than in 2001. Through a relentless drive to improve productivity while reducing costs, we were able to increase margins faster than revenue, distinguishing us from many of our competitors.

Our first priority in improving operations continues to be *upgrading our talent*. In reaction to the soft economy, many of our competitors turned to "organizational leveling mechanisms" that involved across-the-board personnel reductions. We took the opposite approach and more sharply differentiated between employees' contributions to further strengthen our performance culture throughout the company. So, while the soft markets required us to reduce our net employment by more than 1,000 people, we continued to be aggressive at hiring hundreds of talented individuals to strengthen our organization. Of the top 400 leaders in the corporation, 92% are new to their positions since January 1998, roughly half through internal promotions and half through external recruiting. In addition to a strong leadership team, we have built dramatically better depth behind them, to provide the next generation of leadership.

Further strengthening our organization remains a top priority in 2002. We want to make sure we have attractive career paths for every function, in every business and in every geography.


Our *quality and productivity initiatives* are a major driver of improving customer satisfaction and a big contributor to expanding our operating margins by 1,000 basis points over the past four years, from 4% to 14%. We've shown excellent results from rationalizing the number of manufacturing sites, shifting more of our manufacturing into Asia, consolidating the supplier base, deploying Six Sigma® quality and implementing lean manufacturing.

We're also providing tools to assist the teams in improving accounts receivable, inventory and accounts payable processes. To reinforce the importance of this initiative, we've realigned the bonus plans of our top 700 leaders to reflect an equal weighting between cash flow and income growth targets.

**"While we have made great progress in expanding our operating margins and cash flow, we still have excellent opportunities ahead."**

Twenty-five percent of our production now comes from low-cost facilities in Asia, and more than 330 of our employees are certified as Six Sigma Green or Black Belts, helping to reduce product defects and warranty expense. All of our manufacturing employees are becoming increasingly skilled in lean manufacturing techniques. Overall, our quality and productivity initiatives contributed nearly \$80 million to our bottom line for the year and moved us closer to our goal of becoming the low-cost, high-quality producer in all of our businesses.

Our third initiative to build world-class operations is in improving the elements of working capital. We have recently launched a global program called *C<sup>3</sup> – compressing the cash cycle*, the time between purchasing production materials and receiving customer payments. Our goal is to reduce the number of days in the cash cycle 25% by 2004. By the end of the first quarter 2002, we will have trained every PerkinElmer employee in effective cash flow management.



While we have made great progress in expanding our operating margins and increasing cash flow, we still have excellent opportunities ahead. The organization has developed strong operational skills, actionable improvement tools, and an agenda of future initiatives. With operational momentum accelerating, we are confident of reaching our goal to become the industry's cost and quality leader.

### Driving growth

This year we continued to narrow our business portfolio to focus on the most promising high-growth end markets, like health sciences. We drove this shift in part by acquiring Packard BioScience, a world leader in automated liquid handling, sample preparation, and biochip technologies for the drug discovery market. With this acquisition, our Life Sciences business has become a recognized world leader in providing a broad array of analytical and productivity tools to speed the discovery and development of new drugs. At the same time, we divested four non-strategic businesses and announced our intent to divest our aerospace and semiconductor business, known as Fluid Sciences. This positions the company with an even tighter strategic focus on growth markets.

To build on our leading-edge technology franchise, we increased the speed and efficiency of new product introductions (NPI). All our NPI projects are led by seasoned program managers and staffed by dedicated cross-functional teams. We've more than doubled our R&D spending from 1998 to a projected 8% of sales in 2002, and narrowed the number of active programs to greatly improve our time to market. We now average 15 months to develop a new product, down from 26 months in 1998, a 40% reduction in cycle time. New product highlights from 2001 include EnVision™, a multi-technology benchtop reader for high-throughput screening of drug candidates. It increases throughput by 33% to

20,000 samples per hour, and comes with higher resolution and a smaller footprint. Our new Spectrum™ Spotlight infrared chemical imaging system helps scientists reduce the analysis time for a material sample from days to minutes, resulting in a 60x increase in productivity. And CHROMOS11™ is a portable chromatic dispersion unit that can test the signal strength and performance of fiber optic cables up to 200 kilometers long, and do it 30% faster than our competitors' products. Overall, we launched a record 41 new products, bringing sales from products launched within the past three years to 35% of revenue in 2001, up from only 12% in 1998.

*"To build on our leading-edge technology franchise, we increased the speed and efficiency of new product introductions."*

In 2002, we'll continue to focus our growth efforts in health sciences, a fast growing market of tomorrow, where we contribute to improving the quality of human life. Trends in worldwide demographics and technology innovation continue to drive growth in many aspects of prevention and treatment. Our Life Sciences business leads the world in neonatal screening for genetic defects. On the clinical side, our Optoelectronics business provides sensors and diagnostic imaging for prevention of disease – including the digital imaging done through amorphous silicon technology that enables precise, digital x-rays. And on the delivery side, we provide increasingly efficient tools for the discovery of new drugs. The future holds the promise of highly precise healthcare through digital tools, with fewer side effects from drugs and treatment processes. We are determined to be known as a leading innovator in health sciences and to grow rapidly within this marketplace. We also will continue pursuing selected high-growth opportunities in broadband communications, to build on our leading position in high-speed, optical fiber receivers.

Acquisitions are an important part of our growth strategy. Our strong balance sheet, particularly in a soft economic environment, affords us an exceptional opportunity to consolidate the fragmented industries in which we compete.

**"Our strong balance sheet affords us an exceptional opportunity to consolidate the fragmented industries in which we compete."**

We also have an excellent track record in integrating acquisitions, and can apply the learning from these experiences to make future mergers even more efficient. Through organic growth and acquisitions, we expect to grow revenues from health sciences and communications to 80% of our total revenue by 2004, up from our current 55%.

We are excited about the opportunities ahead. While the economic environment remains uncertain in the short-term, we have the fundamentals in place – leading technology, skilled and highly motivated people, and robust operating processes – to ensure PerkinElmer's continued growth over the long-term, and to deliver the performance that you, our shareholders, have come to expect.

I look forward to reporting our progress to you.

Sincerely,



Gregory L. Summe  
Chairman and Chief Executive Officer



**Terrance L. Carlson**  
Senior Vice President,  
Business Development  
and General Counsel

**Robert F. Friel**  
Senior Vice President  
and Chief Financial  
Officer

**Richard F. Walsh**  
Senior Vice President,  
Human Resources


# Life Sciences

At PerkinElmer Life Sciences, we're making progress in our commitment to take a lead role in the life sciences revolution, helping to improve the quality and longevity of people's lives.

Since 1999, we've enhanced our market position substantially. We've invested more than \$1 billion into our Life Sciences business, building significant critical mass in our breadth of products, depth of technology and sales reach. During the past year, we completed the integration of NEN Life Sciences and closed the acquisition of Packard BioScience.

**PerkinElmer Life Sciences is a leading global provider of drug discovery, research and genetic disease screening solutions for customers in the academic, biotechnology, clinical and pharmaceutical industries.**

We further enhanced our position as a technology leader by implementing an aggressive go-to-market strategy and launching a record number of products and technologies. Life Sciences also entered into a number of strategic alliances that enable us to offer complete solutions to our customers, integrating instrumentation, reagents, consumables and informatics to improve their productivity and competitiveness.




Drug Discovery



Genetic Disease Screening

In addition to being the world's third largest provider of drug discovery tools, PerkinElmer Life Sciences is #1 in drug screening, #1 in automated liquid handling and sample preparation, and #1 in genetic disease screening. In 2001, we delivered 12% organic growth, while expanding our operating margins 80 basis points to more than 18%.

We will continue to strengthen our underlying franchise in Life Sciences by leveraging our leading-edge technology, an extensive application-focused global sales and service front end, a high-performance culture that includes operational excellence and Six Sigma as its underpinnings, and a PerkinElmer brand that is recognized around the world. While growing our business, we'll continue to drive operational improvements through our organization and management processes, delivering on our commitments to customers, investors and employees.





*(from left to right)*

**John J. Engel**  
President, Life Sciences

**Frank R. Witney**  
President, Drug Discovery

# Analytical Instruments


At PerkinElmer Instruments, we continue to improve performance as we focus on innovation and higher growth applications.

In 2001, we expanded margins through aggressive productivity and quality initiatives, producing a 280 basis point expansion in operating margins to 13%. We also strengthened our leadership in innovation. During the year, we launched 14 new products, including a successful TurboMass™ Gold Gas Chromatograph Mass Spectrometer, the innovative Spotlight FT-IR imaging system and AssureID™, a workflow-oriented quality control system for pharmaceutical companies. In recognition of these efforts, PerkinElmer Instruments received several industry awards, including the 2001 *Today's Chemist at Work* Readers' Choice Award for Technical Innovation.

**PerkinElmer Instruments provides application-specific analytical solutions for the pharmaceutical, environmental, food and beverage, chemical and semiconductor industries.**

An exclusive distribution agreement with Seiko Instruments extended our thermal analysis product line, and the acquisition of the acclaimed LABWORKS™ laboratory information management system enhanced our growing informatics portfolio. The unit also refocused its efforts on core business competencies by divesting several non-strategic product lines, and decreased manufacturing floor space by over 40% through the aggressive implementation of lean manufacturing practices.


In 2002, PerkinElmer Instruments will focus on improving the customer's experience, from initial system purchase to ongoing training and support, while shifting to higher growth applications. We will launch new inorganic and chromatography products along with Enhanced Security Software, a complete suite of solutions aimed at helping pharmaceutical customers transform business processes to a paperless workflow while achieving compliance with government regulations. We will also introduce a high-throughput MALDI TOF Mass Spectrometer for the proteomics market that significantly reduces both sample preparation and analysis time.




Pharmaceutical




Environmental



**Stephen P. DeFalco**  
President, Instruments





John P. Murphy  
President, Optoelectronics

# Optoelectronics

PerkinElmer Optoelectronics is well positioned to drive growth, accelerate productivity, ensure quality and deliver on commitments to customers.


In 2001, the rapid growth of products and applications serving the biomedical industry was offset by continued weakness in the photography, semiconductor and telecom component markets, causing operating margins to contract by 30 basis points. In both areas, however, we continued to progress in innovation.

**PerkinElmer Optoelectronics provides a range of enabling technologies for the biomedical market through its digital imaging, medical sensor and specialty lighting businesses, and is a leading global provider of high-performance receivers and testing equipment for the communications industry.**


In the biomedical area, we successfully launched full production of our cardiac amorphous silicon panels (aSi), the enabling technology for advanced digital x-ray systems. Significant advances were also made across our medical sensors platform, particularly in capnography and anesthesia gas monitoring applications. Innovative single photon counting modules (SPCM), which are used in ultra-sensitive light detection applications, such as drug discovery and DNA sequencing, remain strong market offerings.

Continuing the shift in telecommunications strategy to meet the overall need for bandwidth and speed at the access and metro network layers, Optoelectronics successfully developed both a 10-gigabit avalanche photodiode and 10-gigabit PIN receiver, and introduced the fastest, longest and most reliable portable testing system, the CHROMOS11™.

Moving into 2002, Optoelectronics will continue to focus on biomedical applications where we are able to deliver high-value technology solutions. Enhanced customer service and continued optimization of global supply chain management are among our organizational priorities for the year. The new product development pipeline will incorporate both Six Sigma fundamentals and phase gate review processes to ensure time-to-market commitments are consistently met or exceeded.



Biomedical



Telecommunications

# Corporate Officers

# Board of Directors

<p><b>Terrance L. Carlson</b> Senior Vice President, Business Development and General Counsel</p>
<p><b>Stephen P. DeFalco</b> Senior Vice President; President, Instruments</p>
<p><b>John J. Engel</b> Executive Vice President; President, Life Sciences</p>
<p><b>Robert F. Friel</b> Senior Vice President and Chief Financial Officer</p>
<p><b>John P. Murphy</b> Vice President; President, Optoelectronics</p>
<p><b>Gregory L. Summe</b> Chairman of the Board and Chief Executive Officer</p>
<p><b>Richard F. Walsh</b> Senior Vice President, Human Resources</p>
<p><b>Frank R. Witney</b> Vice President; President, Drug Discovery</p>



**Tamara J. Erickson**  
President, Consulting  
for the Concours Group



**Kent F. Hansen**  
Professor of  
Nuclear Engineering,  
Massachusetts Institute  
of Technology



**John F. Keane**  
Founder and Chairman  
of the Board, Keane, Inc.



**Nicholas A. Lopardo**  
Chairman and Chief  
Executive Officer,  
Susquehanna  
Capital Management,  
LLC




**Alexis P. Michas**  
Managing Partner  
and Director, Stonington  
Partners, Inc.



**Michael C. Ruetters**  
Executive Chairman,  
EMC Corporation



**Dr. Vicki L. Sato**  
President, Vertex  
Pharmaceuticals, Inc.



**Gabriel Schmergel**  
Retired Chief Executive  
Officer and President,  
Genetics Institute, Inc.



**Kenton J. Sicchitano**  
Retired Global  
Managing Partner,  
PricewaterhouseCoopers  
LLP



**Gregory L. Summe**  
Chairman of the Board  
and Chief Executive  
Officer, PerkinElmer, Inc.



**G. Robert Tod**  
Retired Vice Chairman,  
President, Chief  
Operating Officer  
and Director, CML  
Group, Inc.

# Financial Report 2001

Management's Discussion and Analysis of Results of Operations and Financial Condition	14
Selected Financial Information	32
Consolidated Income Statements	33
Consolidated Balance Sheets	34
Consolidated Statements of Stockholders' Equity	35
Consolidated Statements of Cash Flows	36
Notes to Consolidated Financial Statements	38
Report of Independent Public Accountants	64

## Management's discussion and analysis

### of results of operations and financial condition

#### Overview

PerkinElmer, Inc. is a global high technology company which designs, manufactures, markets and supports products, systems and service offerings within three major business segments: Life Sciences, Optoelectronics and Analytical Instruments. PerkinElmer Life Sciences is a leading global provider of drug discovery, genetic disease screening and research solutions for the life sciences industry. PerkinElmer Life Sciences customers throughout the world are involved in a broad range of research efforts connected with the detection, treatment and cure of disease. PerkinElmer Optoelectronics provides a broad range of high-performance industrial and commercial applications used in the biomedical, telecommunication and other specialty end-markets. PerkinElmer Analytical Instruments is a leading producer and distributor of sophisticated analytical instruments for the pharmaceutical, environmental and general analytical markets. The Company employs approximately 9,700 employees and operates in over 125 countries. For 2001, the Company derived approximately 56% of its revenues from outside of the United States. The Company has approved separate plans to sell its Fluid Sciences business and Security and Detection business and has classified these businesses as discontinued operations. Discussions of Consolidated Results of Operations for the periods presented are on a continuing operations basis.

#### Portfolio changes

2001 represented the fourth year in the Company's transformation into a global, high technology leader. During 2001, the Company continued its focus on shifting its portfolio of businesses to higher growth markets and applications. Significant changes to the Company's portfolio during the three years ended December 30, 2001 are highlighted below:

##### *2001*

- Acquisition of Packard BioScience Company
- Approval of plan to dispose of Fluid Sciences business
- Agreement to dispose of Security and Detection business
- Disposal of Instruments for Research and Applied Science business
- Disposal of Voltarc Technologies business

##### *2000*

- Acquisition of NEN Life Sciences, Inc. ("NEN")
- Disposal of the Berthold business
- Disposal of micromachined sensors business

##### *1999*

- Acquisition of the Analytical Instruments business from PE Corp. ("AI")
- Disposal of the Technical Services business

### **Other accomplishments**

Other significant accomplishments during 2001 included:

- Announced a record number of new product introductions
- Integration of NEN Life Sciences, acquired during 2000
- Strengthening of Life Sciences business through further consolidation of Life Sciences European sales, marketing and administrative functions in Brussels, consolidation of certain North American production sites and establishment of production capabilities in lower cost sites in Asia
- Reorganization of Optoelectronics segment, including the elimination of several manufacturing sites through moves to lower cost manufacturing geographies in Canada and Asia
- Consolidation within Analytical Instruments segment including starting the consolidation of European administrative functions to a central location in Monza, Italy, move to new world headquarters and manufacturing facility in Shelton, CT and moves of certain manufacturing functions from Europe to lower cost geographies within Asia

*As a result of the significant amount of changes, the results period over period are frequently not comparable. In order to improve the comparability of financial results, the Company has highlighted nonrecurring items in all periods and presented a discussion of the results excluding these items. Nonrecurring items represent income and expenses associated with an acquisition, restructuring, divestiture or other unusual event that are not expected to have an impact on ongoing operations.*

### **2001 Acquisitions and Divestitures**

On November 13, 2001, the Company completed the acquisition of Packard BioScience Company ("Packard") for consideration of approximately \$762 million in the form of approximately 22 million common shares and the assumption of \$118 million in debt. The acquisition extends the Company's capabilities in automated liquid handling and sample preparation and strengthens the Company's position as a global provider of comprehensive drug discovery solutions. Packard, a global developer, manufacturer and marketer of instruments, software and related consumables and services for use in drug discovery and other life sciences research, generated sales of approximately \$165 million for its year ended December 31, 2000.

Packard's operations, assumed as of the date of acquisition, are reported within the results from operations of the Life Sciences segment. The acquisition was accounted for as a purchase in accordance with the recently issued Financial Accounting Standards Board Statement No. 141, Business Combinations, ("SFAS No. 141"), and the Company has accordingly allocated the purchase price of Packard based upon the fair values of the net assets acquired and liabilities assumed. The allocation of the purchase price has not yet been finalized; however, the Company does not expect material changes. Portions of the net assets acquired and liabilities assumed were valued by independent appraisers utilizing customary valuation procedures and techniques. These intangible assets included \$69.0 million in acquired in-process research and development for projects that had not yet reached technological feasibility as of the acquisition date and for which no future alternative use existed. These costs were expensed during the fourth quarter of 2001. Other acquired intangible assets valued at \$237.3 million included the fair value of trade names, trademarks, patents and developed technology. Of this amount, \$76.5 million has been ascribed to trade names and trademarks for which an indefinite life has been assigned. The Packard acquisition also resulted in goodwill of \$438.6 million, which is not being amortized in accordance with SFAS No. 141, effective for all business combinations completed subsequent to July 1, 2001.

During the fourth quarter of 2001, the Company sold its Instruments for Research and Applied Science business ("IRAS") and its Voltarc Technologies ("Voltarc") business. These sales resulted in a gain of \$32.3 million and a loss of \$6.3 million, respectively. Additionally, the Company has deferred gains of approximately \$3.0 million in connection with certain contingencies related to the IRAS sale. The combined net income of these businesses was \$1.4 million in 2001 through date of disposal and \$5.4 million in 2000.

## Management's discussion and analysis

### of results of operations and financial condition

The Packard acquisition and 2001 dispositions are expected to result in a higher concentration of revenue in the Life Sciences segment in future periods.

### Adjusted Income from Operations

The following table presents Adjusted Net Income, which excludes goodwill and intangibles amortization and the impact of nonrecurring items:

<i>(In thousands)</i>	12 Months Ended	
	December 30, 2001	December 31, 2000
Sales	\$ 1,330,054	\$ 1,335,532
Cost of sales	706,322	753,332
Research and development costs	81,315	76,920
Selling, general and administrative expenses	350,676	340,004
Adjusted operating income from continuing operations	191,741	165,276
Other expense, net	34,069	34,593
Adjusted income from continuing operations before income taxes	157,672	130,683
Provision for income taxes	40,852	36,364
Adjusted income from continuing operations, net of income tax	\$ 116,820	\$ 94,319

The following table reconciles Adjusted income from continuing operations to Net Income on a reported basis:

<i>(In thousands)</i>	12 Months Ended	
	December 30, 2001	December 31, 2000
Adjusted income from continuing operations before income taxes	\$ 157,672	\$ 130,683
Continuing operations nonrecurring items:		
Acquisition-related charges	(70,540)	(26,118)
Gains on dispositions, net	26,630	35,089
Gains on sale of investments, net	4,274	900
Restructuring charges, net	(9,500)	(3,900)
Reorganization-related charges	(14,298)	(4,109)
Integration-related charges	(5,982)	(3,065)
Telecom component inventory write-down	(4,000)	—
Incentive payments	(7,473)	—
Other	(332)	444
Net nonrecurring items	(81,221)	(759)
Goodwill and intangibles amortization	(42,297)	(30,947)
Income from continuing operations before income taxes	34,154	98,977
Provision for income taxes	(34,774)	(39,699)
(Loss)/income from continuing operations	(620)	59,278
Gain/income from discontinued operations, net of income taxes	35,125	31,242
Net income	\$ 34,505	\$ 90,520

Note: Certain components within the Nonrecurring item captions for the prior year have been adjusted in some instances for ease of comparability to current year. References to reported results refer to US GAAP whereas adjusted results reflect the US GAAP results excluding the impact of goodwill and intangible amortization and the impact of nonrecurring items.

## Discussion of Consolidated Results of Operations – 2001 Compared to 2000

### Sales

#### *2001 Compared to 2000*

Sales for 2001 were \$1,330.1 million versus \$1,335.5 million during 2000, representing a decrease of \$5.4 million or less than 1%. Incremental revenue of approximately \$102 million from the acquisitions of Packard and NEN mostly offset lower revenue of \$74 million associated with divested businesses, the negative impact of foreign exchange of \$26 million and organic revenue decline of \$8 million. Organic revenue, which the Company defines as growth in historical businesses plus growth in acquired businesses assuming they were owned in prior periods, adjusted for the effects of exited businesses and foreign exchange, was strong in the Life Sciences segment as a result of market expansion and new product introductions, but was offset by declines in electronic-based end-markets.

#### *2000 Compared to 1999*

Sales for 2000 were \$1,335.5 million versus \$1,050.8 million in 1999, representing an increase of \$284.7 million or 27%. Incremental revenue from the acquisition of NEN and AI, organic growth in the Life Sciences and Optoelectronics segments as well as new product introductions within the Life Sciences segment contributed to the increase.

### Cost of Sales

#### *2001 Compared to 2000*

Reported cost of sales of \$721.7 million for 2001 versus \$756.9 million during 2000 represented a decrease of \$35.2 million or 5%. On a percentage-of-sales basis, cost of sales decreased to 54% in 2001 from 57% during 2000. The decrease is reflective of the Company's continued productivity and cost containment gains in the form of headcount and facility rationalization and further expansion and relocation into lower cost manufacturing geographies as well as strategic moves into higher margin businesses.

Adjusted cost of sales, which excludes the impact of nonrecurring items, was \$706.3 million for 2001 versus \$753.3 million for 2000, representing a \$47.0 million or 6% decrease. Nonrecurring items for 2001 of \$15.4 million related principally to an inventory write-off due to unexpected declines in the telecom component business, the amortization of the write-up of Packard inventory included as part of purchase accounting, the cost of movements of manufacturing facilities and charges associated with moves to lower cost geographies. The results from 2000 included \$3.6 million in nonrecurring charges as discussed below.

#### *2000 Compared to 1999*

Reported cost of sales of \$756.9 million for 2000 versus \$624.7 million for 1999 represented an increase of \$132.2 million or 21%. On a percentage-of-revenue basis, cost of sales decreased to 57% in 2000 from 59% in 1999. The decrease reflected productivity initiatives and the benefits of restructuring initiatives aimed at headcount reduction and facility rationalization.

Adjusted cost of sales, which excludes the impact of nonrecurring items, was \$753.3 million for 2000 versus \$614.5 million in 1999. Nonrecurring items for 2000 included \$3.6 million in charges associated with reorganization-related activities and the write-up of inventory acquired as part of the NEN acquisition. The results for 1999 included \$10.2 million in nonrecurring charges, principally comprised of the write-up of inventory acquired as part of the AI acquisition.

## Management's discussion and analysis

### of results of operations and financial condition

#### **Research and Development and In-Process Research and Development Charges**

##### *2001 Compared to 2000*

Reported research and development expenses including in-process research and development charges increased to \$150.4 million in 2001 from \$101.2 million in 2000, an increase of \$49.2 million or 49%, as a result of higher in-process research and development charges in 2001. Research and development efforts during 2001 were mainly directed in the end markets of drug discovery tools, pharmaceutical and biomedical within the Life Sciences business.

Adjusted research and development costs, which exclude the impact of nonrecurring items, were \$81.3 million in 2001 versus \$76.9 million in 2000, an increase of \$4.4 million or 6%. As a percentage of sales, research and development costs on an adjusted basis represented 6% of sales for both 2001 and 2000, a trend reflective of the Company's continued commitment to new product development. Nonrecurring items in 2001 were \$69.0 million associated with the write-off of in-process technology acquired as part of the Company's acquisition of Packard. The results from 2000 included a similar charge of \$24.3 million related to the Company's acquisition of NEN.

##### *2000 Compared to 1999*

Reported research and development costs including in-process research and development charges of \$101.2 million for 2000 versus \$89.9 million for 1999 represented an increase of \$11.3 million or 13%. The increase reflects research and development efforts as a result of the Company's continued commitment to new product development, particularly in the Life Sciences businesses.

Adjusted research and development costs for 2000 were \$76.9 million, versus \$66.9 million for 1999. On a percentage-of-sales basis, adjusted research and development costs were 6% for both 2000 and 1999. Nonrecurring charges for 2000 were \$24.3 million, which represented a write-off of in-process research and development charges associated with the NEN acquisition. Nonrecurring charges for 1999 were \$23.0 million, which represented a similar write-off related to the AI acquisition.

#### **Selling, General and Administrative Expenses**

##### *2001 Compared to 2000*

Reported SG&A expenses for 2001 were \$411.1 million versus \$375.9 million for 2000, representing an increase of \$35.2 million or 9%. The increase primarily reflects the inclusion of expenses associated with Packard's operations of \$9 million assumed during the fourth quarter of 2001, increased amortization expenses associated with the NEN and Packard acquisitions of \$11.3 million as well as the restructuring and reorganization related charges noted below.

Adjusted SG&A expenses, which exclude goodwill and intangibles amortization and the impact of nonrecurring items, were \$350.7 million for 2001 versus \$340.0 million for 2000, representing an increase of \$10.7 million or 3% principally as a result of the acquisition of Packard. As a percentage of sales, adjusted SG&A expenses were 26% in 2001 versus 25% in 2000. Goodwill and intangibles amortization increased to \$42.3 million in 2001 from \$30.9 million in 2000 as a result of the NEN acquisition completed in 2000 and the Packard acquisition completed during the fourth quarter of 2001. Nonrecurring charges of \$18.1 million in 2001 included: incentive payments associated with portfolio changes, charges associated with the integration of general and administrative functions for the Life Sciences and Analytical Instruments business units, as well as moves of certain manufacturing operations to lower cost geographies and acquisition-related charges borne by the Company. Nonrecurring charges during 2000 were \$5.0 million as discussed below.

### *2000 Compared to 1999*

Reported SG&A expenses of \$375.9 million for 2000 versus \$290.8 million for 1999 represented an increase of \$85.1 million or 29%. The increase is primarily attributable to the increased amortization expense associated with the AI and NEN acquisitions.

Adjusted SG&A expenses, which excludes goodwill and intangible amortization and the impact of nonrecurring items, were \$340.0 million in 2000 versus \$271.3 million in 1999. As a percentage of sales, adjusted SG&A expenses were 25% in 2000 versus 26% in 1999. Goodwill and intangible amortization increased to \$30.9 million in 2000 from \$22.9 million in 1999. Net nonrecurring charges of \$5.0 million in 2000 represented an increase over the \$3.4 million net gains from 1999. Nonrecurring charges for 2000 included integration-related charges associated with the Packard acquisition. Nonrecurring charges for 1999 included smaller items of a similar nature in connection with the AI acquisition.

## **Restructuring and Asset Impairment Charges**

### *2001 Compared to 2000*

Net restructuring charges were \$9.5 million for 2001 versus \$3.9 million in 2000. Charges for the 2001 year represented a restructuring charge associated with the Packard acquisition of \$3.9 million as well as additional funding for amendments to existing plans for integration activities previously identified. Resultant charges for both years are considered nonrecurring in the Company's presentation of Adjusted Net Income.

### *2000 Compared to 1999*

Net restructuring charges were \$3.9 million in 2000 versus \$14.7 million in 1999. Net charges for 2000 were comprised of a \$15.1 million plan announced during the fourth quarter of 2000, offset by \$11.2 million in reversals associated with plans announced during prior years. The charges during 2000 related to restructuring activities within the Life Sciences and Optoelectronics businesses. Net charges for 1999 were comprised of an \$18.0 million charge for the 1999 plan, offset by \$3.3 million reversed from the 1998 plan. Results from 1999 also included \$18.0 million in asset impairment charges associated with impairments recognized on long-lived assets within the Analytical Instruments and Optoelectronics segments. These charges are considered nonrecurring in the Company's presentation of Adjusted Net Income.

## **Gains on Dispositions**

### *2001 Compared to 2000*

Dispositions resulted in a net gain of \$26.6 million for 2001 versus a net gain of \$35.1 million in 2000. The gain in 2001 resulted principally from the \$32.3 million gain on the sale of the Instruments for Research and Applied Sciences business, previously part of the Analytical Instruments business, and approximately \$0.6 million in net gains resulting from dispositions in the Optoelectronics and Analytical Instruments businesses, offset in part by the \$6.3 million loss resulting from the sale of the Voltarc Technologies business, previously part of the Optoelectronics segment. The gain in 2000 included a gain of approximately \$16.7 million on the sale of a building, a \$10.0 million gain on the disposition of the Company's Berthold business, \$6.7 million in gains from other dispositions within the Optoelectronic business segment and \$1.6 million in gains previously deferred from prior dispositions. The resulting impact for both years is considered nonrecurring in the Company's presentation of Adjusted Net Income.

### *2000 Compared to 1999*

Dispositions resulted in gains of \$35.1 million in 2000 versus \$13.8 million in 1999. The gain in 2000 included amounts related to the sale of a building and dispositions of certain businesses, as previously discussed. The 1999 gain principally related to previously deferred sales proceeds recognized as a result of the favorable resolution of certain events and contingencies. The resulting impact for both years is considered nonrecurring in the Company's presentation of Adjusted Net Income.

# Management's discussion and analysis

## of results of operations and financial condition

### Other Expense, net

#### *2001 Compared to 2000*

Other expense, net for 2001 was \$29.8 million versus \$33.7 million in 2000, representing a decrease of \$3.9 million or 12%. Other expense, net consisted principally of interest from debt associated with prior acquisitions. The decrease is caused primarily by the impact of nonrecurring gains, which consisted of gains realized on the sale of investments of \$4.3 million and \$0.9 million in 2001 and 2000, respectively.

Other expense, net excluding nonrecurring items was \$34.1 million versus \$34.6 million. Decreased interest rates offset the impact of higher average debt levels resulting from the acquisition of NEN in 2000.

#### *2000 Compared to 1999*

Other Expense, net for 2000 was \$33.7 million versus \$15.0 million in 1999, an increase of \$18.7 million. The increase is primarily the result of increased debt levels as a result of acquisitions, as well as the impact of foreign exchange losses. As discussed, the 2000 expense includes a \$0.9 million nonrecurring gain associated with the sale of an investment. The 1999 results did not include any nonrecurring amounts.

### Provision for Income Taxes

#### *2001 Compared to 2000*

Provision for income taxes was \$34.8 million for 2001 versus \$39.7 million in 2000. The 2001 tax rate was primarily impacted by the tax treatment of in-process research and development charges associated with the Packard acquisition, with a minor benefit resulting from a refund on a case previously brought by the Internal Revenue Service. The 2000 rate was impacted to a lesser extent by similar in-process research and development charges, as discussed below.

Provision for income taxes on Adjusted Net Income was \$40.9 million in 2001 and \$36.4 million in 2000. The effective rate on an adjusted basis was 26% for 2001 versus 28% for 2000. The decrease in effective rate was primarily the result of the Company's continued expansion of manufacturing operations to lower tax jurisdictions.

#### *2000 Compared to 1999*

Provision for income taxes was \$39.7 million in 2000 versus \$4.6 million in 1999. The effective rate for both years was 40% on a reported basis and reflected the tax impact of in-process research and development charges for the NEN acquisition during 2000 and the AI acquisition during 1999.

Provision for income taxes on Adjusted net income was \$36.4 million in 2000 versus \$24.7 million in 1999. The effective rate was 28% for both periods on an adjusted basis.

### Segment Results of Operations

The Company's continuing operations are reported as three segments, reflecting the Company's management methodology and structure. The Company's Technical Services segment, Security and Detection Systems business, previously reported as part of the Company's Instruments segment, and Fluid Sciences business have been classified as discontinued operations in accordance with Accounting Principles Board ("APB") Opinion No. 30, *Reporting the Results of Operations – Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions* ("APB No. 30"). The accounting policies of the segments are the same as those described in the footnotes to the accompanying consolidated financial statements. The Company evaluates performance based on operating profit of the respective segments. The discussion that follows is a summary analysis of the primary changes in operating results by segment for 2001 versus 2000 and 2000 versus 1999.

## Life Sciences

### *2001 Compared to 2000*

Sales for 2001 were \$346.1 million versus \$221.4 million in 2000, representing a \$124.7 million or 56% increase. This increase reflects approximately \$102 million from the combined impact of the inclusion of the results of operations of NEN for a full year and two months of results associated with Packard. The increase was also driven by strong growth in the drug discovery and genetic screening businesses and growth in related consumables resulting from new product introductions and geographic expansions leading to organic growth in excess of 12%.

The reported operating loss for 2001 was \$46.0 million versus a loss of \$3.6 million in 2000 due to the inclusion of purchase accounting and restructuring charges associated with the acquisition of Packard during 2001, partially offset by similar charges during 2000 from the NEN acquisition as discussed below.

Adjusted operating profit excluding goodwill and intangibles amortization and nonrecurring items was \$63.9 million for 2001, which represented a \$24.7 million or 63% increase over that of 2000. As a percentage of sales, adjusted operating profit rose to 18.5% from 17.7% as a result of sales of higher margin products and the impact of productivity and cost containment associated with the consolidation of manufacturing and administrative sites. Goodwill and intangibles amortization was \$23.7 million for 2001 versus \$9.3 million for 2000 as a result of the acquisitions discussed above. Nonrecurring charges during 2001 totaled \$86.2 million, consisting of a \$69.0 million charge associated with acquired in-process research and development, a \$1.5 million charge for the revaluation of acquired inventory, \$3.4 million of net restructuring charges, a \$3.3 million integration incentive associated with the Packard acquisition, \$6.0 million in integration-related charges outside the scope of purchase accounting and a net \$2.8 million in other charges which include the settlement of certain preacquisition contingencies from a prior acquisition. The 2000 reported operating profit included \$33.5 million in nonrecurring charges as discussed below.

### *2000 Compared to 1999*

Sales of \$221.4 million for 2000 increased \$63.4 million, or 40%, versus 1999. Organic revenue growth for 2000 was 18%. Higher volumes from high throughput screening and drug discovery applications, revenues from new product introductions in the areas of genetic screening and drug discovery tools, and the inclusion of revenues from NEN Life Sciences acquired in August 2000, were the primary drivers of the increase in 2000 versus 1999.

Reported operating loss for 2000 was \$3.6 million versus reported operating income of \$15.8 million in 1999. The decline is attributed principally to the impact of purchase accounting and restructuring charges associated with the acquisition of NEN.

Adjusted operating profit before goodwill and intangibles amortization and nonrecurring items for 2000 was \$39.2 million, representing an increase of \$15.2 million, or 63%, versus 1999. Higher revenues discussed above, particularly sales of higher-margin new products, and revenues from the NEN acquisition contributed to the increase in operating profit before goodwill and intangibles amortization and nonrecurring items in 2000 versus 1999. The 2000 reported operating loss included goodwill and intangibles amortization of \$9.3 million and nonrecurring charges of \$33.5 million: a \$24.3 million charge for acquired in-process R&D, a \$1.8 million charge for the revaluation of acquired inventory, \$3.9 million of net restructuring charges and \$3.5 million of integration-related charges associated with the NEN acquisition borne by the Company. The 1999 reported operating profit included goodwill and intangibles amortization of \$2.4 million and net restructuring charges of \$5.8 million.

# Management's discussion and analysis

## of results of operations and financial condition

### **Optoelectronics**

#### *2001 Compared to 2000*

Sales for 2001 were \$415.7 million, down \$81.2 million or 16% from the \$496.9 million in sales for 2000. The lower revenue was a result of an organic revenue decline of 10% as well as the impact of divested businesses and product lines. This decline in organic revenue reflects continued weakness in the photography, semiconductor and telecom component markets which more than offset strong growth in the digital imaging, sensors and biomedical markets.

Reported operating profit for 2001 was \$45.8 million, down \$51.1 million or 53% from the \$96.9 million recognized during 2000. The decline was driven principally by the decreases in revenue discussed above, and the costs associated with moving to lower cost production locations and streamlining operations.

Adjusted operating profit for 2001 was \$68.6 million, representing a \$15.0 million or 18% decrease from \$83.6 million for 2000. As a percentage of sales, adjusted operating profit was 16.5% for 2001 versus 16.8% for 2000, with the impact of the reduction in sales offset to some degree by cost savings and productivity enhancements associated with reduced headcount and facility costs as well as moves to lower cost geographies. The 2001 reported operating profit included goodwill and intangibles amortization of \$8.1 million as well as nonrecurring items of \$14.7 million. Nonrecurring items were primarily comprised of a \$4.0 million inventory write-off related to unexpected declines in end-user demand in the telecom component business, a \$5.5 million net loss realized on the disposal of certain businesses, a \$1.8 million retention incentive, reorganization-related charges of \$6.0 million associated with the Company's further expansion and relocation into lower cost manufacturing locations, restructuring and other charges of \$1.0 million as well as a \$3.6 million nonrecurring credit related to accruals no longer deemed necessary. The 2000 reported operating profit included goodwill and intangibles amortization of \$8.1 million and net nonrecurring gains of \$21.4 million, as discussed below.

#### *2000 Compared to 1999*

Sales for 2000 were \$496.9 million versus \$447.7 million in 1999, representing an increase of \$49.2 million, or 11%. Organic revenue growth for 2000 was 22%. Strong revenue growth across all businesses contributed to this increase in 2000 versus 1999.

Reported operating profit increased \$56.6 million in 2000 to \$96.9 million versus \$40.3 million in 1999, representing a 140% increase. The increase in 2000 was due primarily to higher revenues discussed above, the sale of higher margin new specialty lighting products and the continued benefits of Six Sigma and other manufacturing initiatives and the nonrecurring credits discussed below.

Adjusted operating profit before goodwill and intangibles amortization and nonrecurring items for 2000 was \$83.6 million, increasing \$25.3 million, or 43%, versus 1999. The 2000 reported operating profit included goodwill and intangibles amortization of \$8.1 million and net nonrecurring gains of \$21.4 million. Nonrecurring items included: gains on dispositions of \$23.4 million, restructuring credits of \$9.9 million, restructuring charges of \$10 million and restructuring-related charges of \$1.9 million related to the shift by the Company to lower-cost manufacturing geographies. The 1999 reported operating profit included goodwill and intangibles amortization of \$9.5 million and nonrecurring items including restructuring charges of \$5.5 million and an asset impairment charge of \$3 million.

### **Analytical Instruments**

#### *2001 Compared to 2000*

Sales for 2001 were \$568.2 million, a decrease of \$49.1 million or 8% versus the \$617.3 million recognized during 2000. The decline in revenue was driven principally by the disposition of the Berthold business in late 2000, which had revenue of \$30 million in the year 2000, as well as the impact of unfavorable foreign exchange of \$14 million in 2001. Organically, the business contracted less than 1%.

Reported operating profit for 2001 was \$78.4 million versus \$56.9 million in 2000, an increase of \$21.5 million or 38%. The increase during 2001 reflects the impact of nonrecurring gains associated with the sale of the Company's IRAS business, net of nonrecurring charges and the benefits of productivity and cost containment actions. Results from 2000 included a net nonrecurring gain of approximately \$10.0 million resulting from the Berthold sale.

Adjusted operating profit before goodwill and intangibles amortization and nonrecurring items was \$72.8 million for 2001 versus \$61.7 million for 2000, representing an \$11.1 million or 18% increase. As a percentage of sales, adjusted operating profit rose from 10.0% to 12.8% driven principally by reductions in headcount of over 350 people as a result of transitioning European manufacturing to lower cost Asian facilities as well as consolidating European sales and back office operations. Adjusted operating profit for 2001 excludes goodwill and intangibles amortization of \$10.5 million and net nonrecurring gains of \$16.1 million. Nonrecurring items included: \$32.1 million in gains realized on the disposal of businesses, a restructuring charge of \$5.3 million, a \$2.3 million incentive payment associated with the successful completion of the divestitures, and \$8.4 million in reorganization-related charges associated with the business' move to lower cost geographies, consolidation of European finance functions and the move to a new US headquarters. Reported operating profit for 2000 included goodwill and intangibles amortization of \$13.5 million and nonrecurring gains of \$8.7 million, as discussed below.

#### *2000 Compared to 1999*

Sales for 2000 were \$617.3 million, increasing \$172.2 million, or 39%, versus 1999. Organic revenue growth in 2000 was basically flat. The increase in reported 2000 revenues versus 1999 was due primarily to the inclusion of the AI business for a full year, partially offset by the Company's sale of its Berthold business in the fourth quarter and the effects of a stronger dollar in 2000.

Reported operating profit for 2000 was \$56.9 million versus an operating loss in 1999 of \$21.4 million. The increase is due primarily to the inclusion of the AI acquisition for a full year in 2000, improvements in manufacturing cost structure and benefits from restructuring actions.

For 2000, adjusted operating profit before goodwill and intangibles amortization and nonrecurring items was \$61.7 million versus \$40.2 million in 1999, representing an increase of \$21.5 million, or 53%. The 2000 reported operating profit included goodwill and intangibles amortization of \$13.5 million and net nonrecurring gains of \$8.7 million. The net nonrecurring items included: a \$10.0 million gain on disposition of the Berthold business, a \$0.9 million gain on the sale of a building and \$2.2 million of reorganization-related charges associated with the integration of the AI acquisition. The 1999 reported operating profit included goodwill and intangibles amortization of \$11 million, certain acquisition-related charges and other nonrecurring items: \$23 million charge for acquired in-process research and development, \$15 million asset impairment charge, \$9.8 million charge for the revaluation of acquired inventory and restructuring-related and other charges of \$2.8 million.

#### **Restructuring and Asset Impairment Charges**

During the fourth quarter of 2001, the Company recorded \$33.0 million as part of a purchase accounting adjustment associated with the Packard acquisition ("the Packard Plan") in accordance with Emerging Issues Task Force Issue No. 95-3, Recognition of Liabilities in Connection with a Purchase Business Combination ("EITF 95-3"). The principal elements of this plan involve approximately \$20.0 million in employee separation expenses, \$3.0 million in expenses associated with the disposal of certain product lines and assets and \$10.0 million in lease and contract termination costs and other expenses. During 2001, the Company announced restructuring charges totaling

## Management's discussion and analysis

### of results of operations and financial condition

\$9.2 million associated with continued integration activities ("the 2001 plan"). The principal elements of this plan included \$7.0 million in employee separation expenses, \$2.1 million in lease and contract termination costs and other expenses and \$0.1 million in expenses associated with the disposal of certain product lines and assets.

<i>(In millions)</i>	Balance at 12/31/2000	Expenditures and Adjustments	Reversal of Existing Provision	2001 Provision	Balance at 12/30/2001
Existing plans	\$47.4	\$(38.5)	\$(0.5)	\$ 0.8	\$ 9.2
Packard plan	—	—	—	33.0	33.0
2001 plan	—	(1.6)	—	9.2	7.6
<b>Totals</b>	<b>\$47.4</b>	<b>\$(40.1)</b>	<b>\$(0.5)</b>	<b>\$43.0</b>	<b>\$49.8</b>

Amounts accrued for under remaining plans include actions announced during the fourth quarter of 2000 associated with employee separation costs and asset disposal costs resulting from the rationalization of certain facilities and the disposal of underutilized assets. These actions occurred in the Life Sciences and Optoelectronics businesses. Additionally, the remaining accrual for existing plans includes amounts accrued for in connection with the AI and NEN acquisitions that occurred during 1999 and 2000, respectively.

Cash outlays during 2001 were approximately \$36.3 million for the above discussed plans. The Company expects to incur approximately \$40-50 million of cash outlays in connection with these plans during 2002.

### Discontinued Operations

In October 2001, the Company announced its plan to sell its Fluid Sciences business. The Company has accounted for the business as a discontinued operation in accordance with APB No. 30 and, accordingly, the results of operations have been segregated from continuing operations and reported as a separate line item on the Company's accompanying consolidated income statements.

During July 2001, the Company announced its intention to sell its Security and Detection Systems business. During January 2002, the Company announced the sale of this business for consideration of approximately \$100 million. The proposed sale is currently being reviewed by the US Department of Justice and is expected to be finalized during the first half of 2002. The Company has accounted for the business as a discontinued operation in accordance with APB No. 30 and, accordingly, the results of operations have been segregated from continuing operations and reported as a separate line item on the Company's accompanying consolidated income statements. The Company does not expect to incur a loss on the sale of either the Fluid Sciences or Security and Detection Systems businesses.

On August 20, 1999, the Company sold the assets of its Technical Services business, including the outstanding capital stock of EG&G Defense Materials, Inc., a subsidiary of the Company, to EG&G Technical Services, Inc., an affiliate of The Carlyle Group LP (the "Buyer"), for approximately \$250 million in cash and the assumption by the Buyer of certain liabilities of the Technical Services business. The Company accounted for the sale of its Technical Services business as a discontinued operation in accordance with APB No. 30. Accordingly, the results of operations have been segregated from continuing operations and reported as a separate line item on the Company's accompanying consolidated income statements.

Sales from the discontinued operations of the Technical Services, Fluid Sciences and Security and Detection Systems businesses were \$271.7 million, \$359.7 million and \$615.1 million during 2001, 2000 and 1999, respectively. The summary operating results of the discontinued operations are outlined in Note 7 to the financial statements.

## Dividends

During 2001, the Company's Board of Directors declared four regular quarterly cash dividends of 7 cents per share each, resulting in an annual rate of 28 cents per share.

## Stock Split

At the Company's 2001 Annual Meeting of Stockholders, an increase in the number of authorized shares of common stock from 100,000,000 shares to 300,000,000 shares was approved. At the April 24, 2001 Board of Directors Meeting a two-for-one stock split was approved. The stock split has been retroactively reflected in these consolidated financial statements.

## Environmental

The Company is conducting a number of environmental investigations and remedial actions at current and former Company locations and, along with other companies, has been named a potentially responsible party (PRP) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company's responsibility is established and when the cost can be reasonably estimated. The Company has accrued \$6.9 million as of December 30, 2001, representing management's estimate of the total cost of ultimate disposition of known environmental matters. Such amount is not discounted and does not reflect any recovery of any amounts through insurance or indemnification arrangements. These cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the timeframe over which remediation may occur and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that such accrued amounts could be paid out over a period of up to five years. As assessments and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had or are expected to have a material effect on the Company's financial position or results of operations. While it is reasonably possible that a material loss exceeding the amounts recorded may have been incurred, the preliminary stages of the investigations make it impossible for the Company to reasonably estimate the range of potential exposure.

## Liquidity and Capital Resources

### Cash Flows

Net cash provided by operating activities was \$111.0 million in 2001 compared to \$98.2 million in 2000. For 2001, this was comprised of net income before depreciation, amortization and other non-cash items of \$176.8 million partially offset by gains on disposition of assets, net of \$30.9 million and \$34.9 million net change in certain assets and liabilities and other items during 2001. The 2000 operating cash flow was comprised of net income before depreciation, amortization and other non-cash items of \$162.6 million partially offset by gains on dispositions of assets, net of \$37.2 million and \$27.2 million of net change in certain assets, liabilities and other items during the period.

Included in the change in assets and liabilities for 2001 was a \$39.5 million increase in inventory due to lower than planned sales in a number of the businesses, primarily in the Optoelectronics segment and inventory safety stock for production moves, \$31.5 million in restructuring payments, partially offset by a \$14.0 million reduction in accounts receivable which is net of \$37.0 million from a receivable securitization program that is discussed below.

Capital expenditures were \$88.7 million in 2001 versus \$55.3 million in 2000. This increase was due to a \$30 million leasehold improvement at a new worldwide headquarters facility for the Analytical Instruments business and a \$20 million expansion of the Company's telecom manufacturing capability. The Company estimates capital expenditures for 2002 of approximately \$60 million, principally for equipment, process improvement and maintenance associated with increasing productivity and capacity within the businesses of drug discovery tools and other biomedical applications.

## Management's discussion and analysis

### of results of operations and financial condition

Cash flow from the sale of businesses, primarily IRAS and Voltarc, was \$57.5 million and from the monetization of assets was \$56.3 million for 2001. Monetization of assets consisted of the sale of non-strategic assets and the sale-leaseback of facilities and equipment. Costs of acquisitions, net of cash acquired, generated \$45.5 million of cash in 2001, principally from the Packard acquisition, versus a usage of \$431.5 million in 2000. During 2000, cash flow from the sale of businesses was \$49.2 million and from the monetization of assets was \$33.9 million. Monetization of assets during 2000 included the sale of assets, nonstrategic investments and the sale-leaseback of facilities.

Cash flows generated through operating and investing activities, along with proceeds of \$39.4 million from the exercise of stock options, were used in part to reduce short-term commercial paper borrowings by \$177.0 million during 2001. In 2000, the Company issued convertible debt with net proceeds totaling \$448 million. These proceeds along with net borrowings under commercial paper of approximately \$37.0 million and proceeds from the exercise of stock options of \$46.9 million were used in part to reduce other debt balances by approximately \$234.0 million. Cash utilized in the payment of dividends to common stockholders totaled \$28.3 million during 2001.

#### **Borrowing Arrangements**

The Company maintains two unsecured lines of credit totaling \$370 million. In March 2002, the Company's revolving credit facility was refinanced in the amount of \$270 million and will expire in March 2003. In March 2001, the Company's \$100 million revolving credit facility was refinanced and will expire in March 2006. These agreements, which serve as backup facilities for the commercial paper borrowings, have no significant commitment fees. The credit lines, if drawn, bear interest at LIBOR plus 60 basis points. Under the terms of the credit agreement, the Company is required to maintain certain minimum Debt to Total Capital and Interest Coverage ratios. There were no amounts outstanding under these lines at December 31, 2000 or December 30, 2001 nor during any time period in these two years and the Company was in compliance with all applicable covenants.

At December 30, 2001 and December 31, 2000, long-term debt was \$598.1 million and \$583.3 million, respectively. Included in these amounts are \$115 million of unsecured ten-year notes issued in October 1995, which carry an interest rate of 6.8% and mature in 2005. During the fourth quarter of 2001, this fixed rate was swapped to a floating rate, resulting in an all-in cost of funds of 4.46% during 2001, a reduction of 2.34% from the fixed rate. This interest rate swap instrument resets semi-annually in arrears based upon six month USD LIBOR. The fair value of this instrument as of December 30, 2001 was \$(2.3) million which is offset by a corresponding gain on the underlying bond. Other long-term debt includes zero coupon senior convertible debentures described below which had a \$483 million accreted value at 2001 and a \$468 million accreted value at 2000. The carrying amount of the unsecured ten-year notes and senior subordinated ten-year notes approximated the estimated fair value at December 30, 2001, based on a quoted market price. The estimated fair value of the convertible debentures approximated \$512 million at December 30, 2001, also based on a quoted market price.

As discussed above, in 2001 the Company relocated its Analytical Instruments headquarters to a new leased facility and pre-funded \$30 million of leasehold improvements. Originally, these improvements were to be included in the operating lease of the facility. However, the Company determined it was more economical to purchase the leasehold improvements and fund them through asset securitization. Consequently, the Company established a wholly owned consolidated subsidiary to purchase, on a revolving basis, certain of the Company's accounts receivable balances and simultaneously sell an undivided interest in this pool of receivables to a financial institution. As collections reduce the accounts receivable balances, new receivables are sold. The Company's consolidated subsidiary retains the risk of credit loss on the receivables and accordingly, the full amount of the allowance for doubtful accounts has been provided for on the Company's balance sheet. Under the terms of this arrangement, the Company retains collection and administrative responsibilities for the balances. The facility is renewable on an annual basis and has an effective interest rate of approximately LIBOR plus 30 basis points. Amounts sold under this facility during 2001 approximated \$37 million. This amount has reduced the outstanding receivables balance.

In August 2000, the Company sold zero coupon senior convertible debentures with an aggregate purchase price of \$460 million. The Company used the offering's net proceeds of approximately \$448 million to repay a portion of its commercial paper borrowings, which had been increased temporarily to finance the NEN acquisition. Deferred issuance costs of \$12 million were recorded as a non-current asset and are being amortized over three years. The debentures are due August 2020, and were priced with a yield to maturity of 3.5%. At maturity, the Company would be required to repay \$921 million, comprised of \$460 million of original purchase price plus accrued original issue discount. The Company may redeem some or all of the debentures at any time on or after August 7, 2003 at a redemption price equal to the issue price plus the accrued original issue discount through the redemption date. Holders of the debentures may require the Company to repurchase some or all of the debentures in August 2003 and August 2010, or at any time upon certain changes of control in the Company, at a repurchase price equal to the initial price to the public plus the accrued original issue discount through the date of the repurchase. The Company has the right to repay some or all of the debentures with common stock based on the then current market price, subject to satisfying conditions within the trust indenture, particularly the Company's ability to register the necessary common shares under applicable securities laws. The Company may only exercise this right in connection with a repurchase at the option of the holders or a repurchase in connection with certain changes in control. The debentures are currently convertible into 10.8 million shares of the Company's common stock at approximately \$44 per share.

In November 2001, the Company completed its acquisition of Packard BioScience Company and assumed \$118 million of senior subordinated ten-year notes issued in March 1997. The Company redeemed the notes on March 1, 2002 at a rate of 104.688% in accordance with the indenture dated as of March 4, 1997. As such, this amount has been reclassified to short-term for presentation purposes.

As of December 30, 2001, the Company was in compliance with all covenants and other requirements set forth in its credit agreements and indentures. Although a downgrade in the Company's credit rating could affect the pricing of short-term liquidity sources such as commercial paper, the only credit agreement or indenture the Company maintains with ratings downgrades that would accelerate the maturity dates of debt is the receivables securitization program discussed above. The Company and its subsidiaries are parties to various other financing and leasing arrangements which do not contain any ratings triggers.

### Contractual Obligations

The following table summarizes the Company's contractual obligations at December 30, 2001, and the effect such obligations are expected to have on its liquidity and cash flow in future periods:

<i>(Dollars in thousands)</i>	Operating Leases	6.800% Unsecured Notes due 2005 <sup>1</sup>	9.375% Sr. Subordinated Notes due 2005 <sup>2</sup>	Total	Zero Coupon Convertible Debentures due 2020 <sup>3</sup>
2002	\$ 20,000	\$ 7,820	\$ 118,145	\$ 145,965	\$ —
2003	17,400	7,820	—	25,220	510,466
2004	15,400	7,820	—	23,220	—
2005	12,100	122,820	—	134,920	—
2006+	127,800	—	—	127,800	—
<b>Total</b>	<b>\$ 192,700</b>	<b>\$ 146,280</b>	<b>\$ 118,145</b>	<b>\$ 457,125</b>	<b>\$ 510,466</b>

<sup>1</sup> The interest on the Unsecured notes maturing in 2005, originally fixed at 6.8%, has been swapped to a variable rate based upon the 6 month LIBOR. For the purposes of this table, the obligation has been calculated using the fixed 6.8% rate due to the variability in the actual rate.

<sup>2</sup> As discussed above, the 9.375% Sr. Subordinated Notes due to 2005 have been redeemed by the Company as of March 1, 2002.

<sup>3</sup> The 2003 obligation on the Zero Coupon Convertible Debentures reflects the right of the holders to require the Company to repurchase some or all of the notes in August 2003, as discussed above. The Company has the option to repay some or all of the debentures with common stock, as discussed above.

## Management's discussion and analysis

### of results of operations and financial condition

Included in the lease commitments disclosed in the preceding table is a six-year operating lease agreement signed in 2000 for a facility in the Optoelectronics segment. At the end of the lease term, the Company, at its option, may: (i) renew the lease; (ii) purchase the property at a price equal to the lessor's original cost (approximately \$30 million); or (iii) allow the lease to expire and cause the property to be sold. The Company's ability to cause the property to be sold depends upon its compliance with certain terms of the lease. Under certain conditions, the Company would receive any excess of the net sales proceeds over the property's original cost. In the event that the net sales proceeds are less than the original cost, the Company would be required to make certain contingent rental payments to the lessor equal to that difference, subject to a maximum amount.

The Company requires cash to pay its operating expenses, make capital expenditures and acquisitions and pay debt service, including principal and interest. The Company's principal sources of funds are from its operations and the capital markets, particularly the debt markets. The Company also anticipates receiving significant cash in the near term from the projected dispositions of its discontinued operations.

In the near term, the Company anticipates that its operations will generate sufficient cash to fund its operating expenses, capital expenditures and interest payments on its debt. Depending on the size of the transaction, the Company may require funds from external sources for acquisitions that it effects for cash. The Company may also require funds from external sources to refinance the principal of its debt as it matures, particularly the \$510 million of zero coupon convertible debentures that holders will have the option to put in 2003 and the \$123 million of principal that becomes due on its 6.8% unsecured notes in 2005.

Principal factors that could affect the Company's internally generated funds include:

- Increased working capital requirements.
- Deterioration of sales due to continued weakness in certain end-markets into which the Company sells.

Principal factors that could affect the Company's ability to obtain cash from external sources include:

- A deterioration in the external credit markets hindering the Company's ability to place investment grade commercial paper.
- The Company's inability to dispose of the Fluid Sciences and Security and Detection Systems businesses currently being held for sale.
- Borrowing requirements stemming from potential obligations noted above that would reduce the Company's overall borrowing capacity.
- The existence of a ratings downgrade that would impact the Company's ability to borrow under its receivable securitization program.

### **Critical Accounting Policies and Estimates**

The preparation of consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, including those related to bad debts, inventories, investments, intangible assets, income taxes, restructuring, pensions and other post-retirement benefits, and contingencies and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The Company believes the following critical accounting policies affect its more significant judgments and estimates used in preparation of its consolidated financial statements.

The Company's product sales are recorded at the time when persuasive evidence of an arrangement exists, delivery has occurred, the price to the buyer is fixed or determinable and collectibility is reasonably assured. A provision is made at the time the related revenue is recognized for the cost of any installation obligations and the estimated cost of product warranties. When other significant obligations remain after products are delivered, including certain customer acceptance provisions, revenue is recognized only after such obligations

are fulfilled. If a loss is anticipated on any contract, a provision for the entire loss is made immediately. Revenue related to the sale of maintenance contracts is deferred and amortized on a straight-line basis over the service period. For equipment leased to a customer under a sales-type lease, revenue recognition generally commences when the equipment has been shipped, installed and is ready for use.

The Company values inventory at the lower of the actual cost to purchase and/or manufacture the inventory or the current estimated market value of the inventory. Inventory quantities on hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on either our estimated forecast of product demand and production requirements for the next twelve months or historical trailing twelve month usage. A significant increase in the demand for our products could result in a short-term increase in the cost of inventory purchases while a significant decrease in demand could result in an increase in the amount of excess inventory quantities on hand requiring additional inventory write-downs.

The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. If the financial condition of the Company's customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

The Company periodically reviews the carrying value of its long-lived assets and investments for continued appropriateness. This review is based upon its projections of anticipated future cash flows, market conditions, legal factors and operational performance. While it believes that its future estimates are reasonable, different assumptions regarding items such as future cash flows and the volatility inherent in markets which we serve could materially affect our evaluations and result in impairment charges against the carrying value of those assets.

## **Quantitative and Qualitative Disclosures About Market Risk**

### **Financial Instruments**

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments and accounts receivable. The Company believes it had no significant concentrations of credit risk as of December 30, 2001.

In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. Transactions covered by hedge contracts include inter-company and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity and are recorded at fair value on the consolidated balance sheet. Credit risk and market risk are minimal as the foreign exchange instruments are contracted with major banking institutions. Unrealized gains and losses on the Company's foreign currency contracts are recognized immediately in earnings for hedges designated as fair value and, for hedges designated as cash flow, the related unrealized gains or losses are deferred as a component of other comprehensive income in the accompanying consolidated balance sheet. These deferred gains and losses are recognized in income in the period in which the underlying anticipated transaction occurs. Effectiveness of these cash flow hedges is measured utilizing the cumulative dollar offset method and is reviewed quarterly. For the year ended December 30, 2001, net losses from hedges reclassified from other comprehensive income to revenue and expense totaled \$36,000. The notional amount of the outstanding foreign currency contracts was approximately \$280 million as of December 30, 2001 and \$190 million at December 31, 2000. At December 30, 2001, the approximate fair value for foreign currency derivative instruments designated as fair value hedges was \$560,000 and at December 31, 2000 was not significant. The approximate fair value for foreign currency derivative instruments designated as cash flow hedges was \$380,000 and is recorded in other current assets with the offset to other comprehensive income. This gain will be recognized in earnings over the next 12 months.

# Management's discussion and analysis

## of results of operations and financial condition

### Market Risk

**Market Risk:** The Company is exposed to market risk, including changes in interest rates and currency exchange rates. To manage the volatility relating to these exposures, the Company enters into various derivative transactions pursuant to the Company's policies to hedge against known or forecasted market exposures.

**Foreign Exchange Risk:** As a multinational corporation, the Company is exposed to changes in foreign exchange rates. As the Company's international sales grow, exposure to volatility in exchange rates could have a materially adverse impact on the Company's financial results. The Company's risk from exchange rates is primarily related to non-dollar denominated sales in Europe and Asia. The Company uses foreign currency forward and option contracts to manage the risk of exchange rate fluctuations. The derivative instruments held by the Company are not leveraged and are not held for trading purposes. The Company uses forward contracts to hedge its net asset position and uses a combination of forward and option contracts to hedge anticipated cash flows. The Company's hedging activity is intended to offset the impact of currency fluctuations on assets, liabilities and cash flows denominated in foreign currencies. The success of the hedging program depends on forecasts of transaction activity in various currencies. To the extent that these forecasts are overstated or understated during periods of currency volatility, the Company could experience unanticipated currency gains or losses. The principal currencies hedged are the British Pound, Canadian Dollar, Euro, Japanese Yen, and Singapore Dollar. In those currencies where there is a liquid, cost-effective forward market, the Company maintains hedge coverage between minimum and maximum percentages of its anticipated transaction exposure for periods not to exceed one year. The gains and losses on these contracts offset changes in the value of the related exposure.

**Interest Rate Risk:** The Company maintains an investment portfolio consisting of securities of various issuers, types and maturities. The investments are classified as available for sale. These securities are recorded on the balance sheet at market value, with any unrealized gain or loss recorded in comprehensive income. These instruments are not leveraged, and are not held for trading purposes.

**Value-at-Risk:** The Company utilizes a Value-at-Risk ("VaR") model to determine the potential loss in fair value of its interest rate and foreign exchange sensitive derivative financial instruments within a 95% confidence interval. The Company's computation was based on the interrelationships between movements in interest rates and foreign currencies. These interrelationships were determined by observing historical interest rate and foreign currency market changes over corresponding periods. The assets, liabilities, firm commitments and anticipated transactions, which are hedged by derivative financial instruments, were excluded from the model. The Company's computations are based on the Monte Carlo simulation, utilizing a 95% confidence interval and a holding period of 30 days. The VaR model is a risk analysis tool and does not purport to represent actual gains or losses in fair value that will be incurred by the Company. The VaR model estimated that there is a 5% chance that the market value of the derivative instruments held as of December 30, 2001 will deteriorate due to foreign currency and interest rate fluctuations by more than \$1.8 million. During the four quarters ended December 30, 2001, the VaR ranged between \$0.25 million and \$1.8 million, and averaged approximately \$0.8 million.

Management periodically reviews its interest rate and foreign currency exposures and evaluates strategies to manage such exposures in the near future. The Company implements changes, when deemed necessary, in the management of hedging instruments which mitigate its exposure.

Since the Company utilizes interest rate and foreign currency sensitive derivative instruments for hedging, a loss in fair value for those instruments is generally offset by increases in the value of the underlying transaction.

It is the Company's policy to enter into foreign currency and interest rate transactions only to the extent considered necessary to meet its objectives as stated above. The Company does not enter into foreign currency or interest rate transactions for speculative purposes.

## Factors Affecting Future Performance

This report contains "forward-looking" statements. For this purpose, any statements contained in this report that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this report. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements:

- Difficulties integrating technologies, operations and personnel of recent acquisitions, including our ability to successfully integrate Packard's operations and employees with ours;
- Our ability to realize anticipated synergies and cost savings from the Packard transaction;
- Our inability to consummate a disposition of the Fluid Sciences business on favorable terms;
- A downturn in our customers' markets or in general economic conditions;
- Our failure to introduce new products in a timely manner;
- Economic, political and other risks associated with international sales and operations;
- Competition from third parties, including pricing pressure, and governmental regulation;
- Our level of debt and the possible incurrence of additional debt in the future, and
- Our failure to achieve expected performance from previously acquired businesses might result in the need to reexamine the associated goodwill and intangible asset balances.

These and other important factors that may affect our actual results are discussed in detail in the risk factors set forth in Amendment No. 1 to our Registration Statement on Form S-4, filed on August 17, 2001 with the Securities and Exchange Commission, under the captions "Risk Factors — Risks Relating to the Merger" and "Risk Factors — Risks Relating to PerkinElmer's Business," which discussion is expressly incorporated by reference in this report.

## Selected Financial Information

for the Five Years Ended December 30, 2001

*(In thousands where applicable)*

	2001	2000	1999	1998	1997
<b>Operations:</b>					
Sales	\$1,330,054	\$1,335,532	\$1,050,835	\$ 545,146	\$653,144
Operating income (loss) from continuing operations	63,949	132,669	26,504	100,922	(8,411)
(Loss) income from continuing operations	(620)	59,278	6,911	71,501	(9,126)
Income from discontinued operations, net of income taxes	32,758	26,789	37,125	30,501	42,818
Gain on dispositions of discontinued operations, net of income taxes	2,367	4,453	110,280	—	—
Net income	34,505	90,520	154,316	102,002	33,692
Basic (loss) earnings per share:					
Continuing operations	(0.01)	0.60	0.08	0.79	(0.10)
Discontinued operations	0.34	0.32	1.62	0.34	0.47
Net income	0.33	0.92	1.69	1.13	0.37
Diluted (loss) earnings per share:					
Continuing operations	(0.01)	0.58	0.07	0.78	(0.10)
Discontinued operations	0.34	0.31	1.58	0.33	0.47
Net income	0.33	0.89	1.66	1.11	0.37
Weighted-average common shares outstanding:					
Basic	103,687	98,212	91,044	90,644	91,514
Diluted	103,687	102,278	93,138	91,768	91,796
<b>Financial Position:</b>					
Total assets	\$2,919,129	\$2,188,333	\$1,663,861	\$1,069,136	\$719,050
Short-term debt	125,741	183,110	382,328	161,548	46,167
Long-term debt	598,125	583,337	114,855	129,830	114,863
Long-term liabilities	249,237	230,987	196,446	124,768	96,014
Stockholders' equity	1,363,557	728,389	550,776	399,667	328,388
Total debt/total capital	35%	51%	47%	42%	33%
Common shares outstanding	124,188	99,548	92,732	89,492	90,666
<b>Cash Flows:</b>					
Cash flows from continuing operations	\$ 110,975	\$ 98,183	\$ 93,743	\$ 15,274	\$ (26,250)
Cash flows from discontinued operations	12,324	47,365	22,086	54,281	23,651
Cash flows from operating activities	123,299	145,548	115,829	69,555	(2,599)
Depreciation and amortization from continuing operations	80,497	65,717	58,749	41,820	31,643
Capital expenditures for continuing operations	88,699	55,318	34,840	33,556	33,638
Purchases of common stock	1,784	10,589	970	41,217	28,104
Cash dividends per common share	.28	.28	.28	.28	.28

*Note: The information presented above includes in-process research and development charges, revaluation of acquired inventory, gains, restructuring and other nonrecurring items discussed in greater detail within Management's Discussion and Analysis of Results of Operations and Financial Condition.*

## Consolidated Income Statements

for the Three Years Ended December 30, 2001

<i>(in thousands except per share data)</i>	2001	2000	1999
Sales			
Products	\$1,167,019	\$1,177,714	\$ 947,594
Services	163,035	157,818	103,241
Total Sales	1,330,054	1,335,532	1,050,835
Cost of sales			
Products	633,629	699,602	541,152
Services	86,596	55,470	73,702
Revaluation of acquired inventory	1,500	1,818	9,857
Total cost of sales	721,725	756,890	624,711
Selling, general and administrative expenses	411,145	375,942	290,773
Research and development expenses	81,315	76,920	66,934
In-process research and development charges	69,040	24,300	23,000
Restructuring charges, net	9,500	3,900	14,677
Asset impairment charges	—	—	18,000
Gains on dispositions, net	(26,620)	(35,089)	(13,764)
Operating income from continuing operations	63,949	132,669	26,504
Other expense, net	(29,795)	(33,692)	(15,008)
Income from continuing operations before income taxes	34,154	98,977	11,496
Provision for income taxes	34,774	39,699	4,585
(Loss) income from continuing operations	(620)	59,278	6,911
Income from discontinued operations, net of income taxes	32,758	26,789	37,125
Gain on disposition of discontinued operations, net of income taxes	2,367	4,453	110,280
Net income	\$ 34,505	\$ 90,520	\$ 154,316
Basic (loss) earnings per share			
Continuing operations	\$ (0.01)	\$ 0.60	\$ 0.08
Discontinued operations	0.34	0.32	1.62
Net income	\$ 0.33	\$ 0.92	\$ 1.69
Diluted (loss) earnings per share			
Continued operations	\$ (0.01)	\$ 0.58	\$ 0.07
Discontinued operations	0.34	0.31	1.58
Net income	\$ 0.33	\$ 0.89	\$ 1.66

*The accompanying notes are an integral part of these consolidated financial statements.*

## Consolidated Balance Sheets

as of December 30, 2001 and December 31, 2000

<i>(In thousands except share and per share data)</i>	2001	2000
Current assets:		
Cash and cash equivalents	\$ 138,250	\$ 125,551
Accounts receivable, net	297,362	292,714
Inventories	242,471	190,526
Other current assets	148,821	169,976
Net assets of discontinued operations	170,535	147,140
<b>Total current assets</b>	<b>997,439</b>	<b>925,907</b>
Property, plant and equipment:		
At cost	427,771	424,141
Accumulated depreciation and amortization	(166,239)	(187,375)
<b>Net property, plant and equipment</b>	<b>261,532</b>	<b>236,766</b>
Investments	29,613	36,226
Intangible assets, net	1,530,608	886,569
Other assets	99,937	102,865
<b>Total assets</b>	<b>\$2,919,129</b>	<b>\$2,188,333</b>
Current liabilities:		
Short-term debt	\$ 125,741	\$ 183,110
Accounts payable	143,357	118,170
Accrued restructuring costs	49,783	47,444
Accrued expenses	389,329	296,896
<b>Total current liabilities</b>	<b>708,210</b>	<b>645,620</b>
Long-term debt	598,125	583,337
Long-term liabilities	249,237	230,987
Commitments and contingencies (Note 17)		
Stockholders' equity:		
Preferred stock – \$1 par value, authorized 1,000,000 shares; none issued or outstanding	—	—
Common stock – \$1 par value, authorized 300,000,000 shares; issued 145,101,000 and 122,908,000 in 2001 and 2000, respectively	145,101	122,908
Capital in excess of par value	641,164	37,060
Retained earnings	842,004	835,917
Accumulated other comprehensive loss	(60,940)	(39,042)
Cost of shares held in treasury – 20,913,000 shares in 2001 and 23,360,000 shares in 2000	(203,772)	(228,454)
<b>Total stockholders' equity</b>	<b>1,363,557</b>	<b>728,389</b>
<b>Total liabilities and stockholders' equity</b>	<b>\$2,919,129</b>	<b>\$2,188,333</b>

*The accompanying notes are an integral part of these consolidated financial statements.*

## Consolidated Statements of Stockholders' Equity

for the Three Years Ended December 30, 2001

<i>(In thousands except per share data)</i>	Comprehensive Income	Common Stock	Retained Earnings	Capital in Excess of Par	Accumulated Other Comprehensive Income (Loss)	Cost of Shares Held in Treasury	Total Stockholders' Equity
Balance, January 3, 1999		\$120,204	\$563,489	\$ —	\$ 3,729	\$(287,755)	\$ 399,667
Comprehensive income:							
Net income	\$154,316	—	154,316	—	—	—	154,316
Other comprehensive income (loss), net of tax							
Foreign currency translation adjustments	(17,804)	—	—	—	(17,804)	—	(17,804)
Unrealized gains on securities arising during the period	93						
Reclassification adjustment	(58)						
Net unrealized gains	35	—	—	—	35	—	35
Other comprehensive loss	(17,769)						
Comprehensive income	<u>\$136,547</u>						
Cash dividends (\$.28 per share)		—	(25,499)	—	—	—	(25,499)
Exercise of employee stock options and related income tax benefits		—	8,369	—	—	20,264	28,633
Issuance of common stock for employee benefit plans		—	1,232	—	—	11,166	12,398
Purchase of common stock for treasury		—	—	—	—	(970)	(970)
Balance, January 2, 2000		120,204	701,907	—	(14,040)	(257,295)	550,776
Comprehensive income:							
Net income	\$ 90,520	—	90,520	—	—	—	90,520
Other comprehensive income (loss), net of tax							
Foreign currency translation adjustments	(25,484)	—	—	—	(25,484)	—	(25,484)
Unrealized gains on securities arising during the period	481						
Reclassification adjustment	1						
Net unrealized gains	482	—	—	—	482	—	482
Other comprehensive loss	(25,002)						
Comprehensive income	<u>\$ 65,518</u>						
Cash dividends (\$.28 per share)		—	(27,533)	—	—	—	(27,533)
Exercise of employee stock options and related income tax benefits		—	16,000	17,230	—	34,939	68,169
Issuance of common stock for employee benefit plans		—	(155)	5,228	—	4,389	9,462
Purchase of common stock for treasury		—	—	(102)	—	(10,487)	(10,589)
Mergers, acquisitions and other		2,704	55,178	14,704	—	—	72,586
Balance, December 31, 2000		122,908	835,917	37,060	(39,042)	(228,454)	728,389
Comprehensive income:							
Net income	\$ 34,505	—	34,505	—	—	—	34,505
Other comprehensive income (loss), net of tax							
Foreign currency translation adjustments	(20,976)	—	—	—	(20,976)	—	(20,976)
Unrealized gains on derivative instruments	1,407	—	—	—	1,407	—	1,407
Unrealized losses on securities arising during the period	(2,438)						
Reclassification adjustment	109						
Net unrealized losses	(2,329)	—	—	—	(2,329)	—	(2,329)
Other comprehensive loss	(21,898)						
Comprehensive income	<u>\$ 12,607</u>						
Cash dividends (\$.28 per share)		—	(28,294)	—	—	—	(28,294)
Exercise of employee stock options and related income tax benefits		—	—	20,723	—	20,047	40,770
Issuance of common stock for employee benefit plans		—	(124)	7,592	—	4,671	11,864
Purchase of common stock for treasury		—	—	—	—	(1,784)	(1,784)
Acquisition of AAS		—	—	3,252	—	1,748	5,000
Acquisition of Packard		22,193	—	572,537	—	—	595,280
Balance, December 30, 2001		\$145,101	\$842,004	\$641,164	\$(60,940)	\$(203,772)	\$1,363,557

The accompanying notes are an integral part of these consolidated financial statements.

# Consolidated Statements of Cash Flows

for the Three Years Ended December 30, 2001

<i>(In thousands)</i>	2001	2000	1999
Operating activities:			
Net Income	\$ 34,505	\$ 90,520	\$ 154,316
Deduct net income from discontinued operations	(32,758)	(26,789)	(37,125)
Deduct net gain on disposition of discontinued operations	(2,367)	(4,453)	(110,280)
(Loss) income from continuing operations	(620)	59,278	6,911
Adjustments to reconcile (loss) income from continuing operations to net cash provided by continuing operations:			
Revaluation of acquired inventory	1,500	1,818	9,857
In-process research and development changes	69,040	24,300	23,000
Non-cash portion of restructuring charges	5,624	2,900	2,300
Asset impairment charges	—	—	18,000
Depreciation and amortization	80,497	65,717	58,749
Amortization of deferred debt issuance cost	3,762	1,762	—
Accretion of discount on issuance of convertible debentures	16,991	6,805	—
Gains on dispositions and sales of investments, net	(30,892)	(37,189)	(15,399)
Changes in assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:			
Accounts receivable	13,974	510	(49,346)
Inventories	(39,504)	(17,890)	9,101
Accounts payable and accrued expenses	31,979	18,625	56,800
Tax benefit from exercise of common stock options	15,043	30,843	5,811
Accrued restructuring costs	(31,509)	(31,474)	(15,823)
Prepaid expenses and other	(24,910)	(27,822)	(16,218)
Net cash provided by continuing operations operating activities	110,975	98,183	93,743
Net cash provided by discontinued operations operating activities	12,324	47,365	22,086
Net cash provided by operating activities	123,299	145,548	115,829
Investing activities:			
Capital expenditures	(88,699)	(55,318)	(34,840)
Proceeds from dispositions of businesses, net	57,545	49,164	—
Proceeds from dispositions of property, plant and equipment and non-strategic investments, net	56,272	33,947	420
Cost of acquisitions and investments, net of cash and cash equivalents acquired	45,458	(431,497)	(296,202)
Net cash provided by (used in) continuing operations investing activities	70,576	(403,704)	(330,622)
Net cash (used in) provided by discontinued operations investing activities	(4,057)	2,274	186,739
Net cash provided by (used in) investing activities	66,519	(401,430)	(143,883)

<i>(Dollars in thousands)</i>	<b>2001</b>	2000	1999
Financing activities:			
Proceeds from issuance of convertible debt	—	448,000	—
(Decrease) increase in commercial paper borrowings	(177,000)	37,000	(10,000)
Other debt (decreases) increases	(1,267)	(233,991)	69,529
Proceeds from issuance of common stock	39,475	46,902	28,923
Purchases of common stock	(1,784)	(10,589)	(970)
Cash dividends	(28,294)	(27,533)	(25,499)
Net cash (used in) provided by continuing operations financing activities	(168,870)	259,789	61,983
Net cash (used in) discontinued operations financing activities	(2,726)	—	—
Net cash (used in) provided by financing activities	(171,596)	259,789	61,983
Effect of exchange rate changes on cash and cash equivalents	(5,523)	(5,006)	(2,844)
Net increase (decrease) in cash and cash equivalents	12,699	(1,099)	31,085
Cash and cash equivalents at beginning of year	125,551	126,650	95,565
Cash and cash equivalents at end of year	\$ 138,250	\$ 125,551	\$ 126,650
Supplemental disclosures of cash flow information for continuing and discontinued operations (see also Note 2):			
Cash paid during the year for:			
Interest	\$ 17,971	\$ 45,236	\$ 28,438
Income taxes	18,211	21,819	82,368
Noncash investing and financing activities:			
One-year secured 5% promissory notes issued to PE Corp. in connection with the acquisition of the Analytical Instruments division (Note 2)	—	—	150,000
Stock issued to Packard shareholders	595,280	—	—
Packard debt assumed	118,432	—	—
Fair value of Packard options exchanged	28,004	—	—

*The accompanying notes are an integral part of these consolidated financial statements.*

# Notes to Consolidated Financial Statements

## Note 1: Nature of Operations and Critical Accounting Policies

**Nature of Operations:** PerkinElmer, Inc. is a global high technology company which designs, manufactures, markets and supports products, systems and service offerings within three major business segments: Life Sciences, Optoelectronics and Analytical Instruments. In August 1999, the Company divested its Technical Services segment, which is presented as discontinued operations in accordance with Accounting Principles Board (APB) Opinion No. 30, *Reporting the Results of Operations – Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions* (“APB No. 30”) (see Note 7). In July 2001, PerkinElmer, Inc. approved a plan to sell its Security and Detection Systems business, which is presented as discontinued operations in accordance with APB No. 30 (see Note 7). In October 2001, PerkinElmer, Inc. approved a plan to sell its Fluid Sciences business which is presented as part of discontinued operations in accordance with APB No. 30 (see Note 7). The consolidated financial statements include the accounts of PerkinElmer, Inc. (formerly EG&G, Inc.) and its subsidiaries (the Company). All material intercompany balances and transactions have been eliminated in consolidation.

**Critical Accounting Policies and Estimates:** The preparation of consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, including those related to bad debts, inventories, investments, intangible assets, income taxes, restructuring, pensions and other post-retirement benefits, and contingencies and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

**Sales:** The majority of the Company's product sales are recorded at the time of shipment and when persuasive evidence of an arrangement exists, the seller's price to the buyer is fixed or determinable and collectibility is reasonably assured. A provision is made at the time the related revenue is recognized for the cost of any installation obligations and the estimated cost of product warranties. When other significant obligations remain after products are delivered, including certain customer acceptance provisions, revenue is recognized only after such obligations are fulfilled. If a loss is anticipated on any contract, a provision for the entire loss is made immediately. Revenue related to the sale of maintenance contracts is deferred and amortized on a straight-line basis over the service period. For equipment leased to a customer under a sales-type lease, revenue recognition generally commences when the equipment has been shipped and installed. Shipping and handling costs are reflected in both revenue and cost of goods sold to the extent they are billed to customers. In all other instances they are reflected as a component of cost of goods sold.

**Inventories:** Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. The majority of inventories is accounted for using the first-in, first-out (FIFO) method of determining inventory costs; remaining inventories are accounted for using the last-in, first-out (LIFO) method. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on either the Company's estimated forecast of product demand and production requirements for the next twelve months or historical trailing twelve month usage. A significant increase in the demand for the Company's products could result in a short-term increase in the cost of inventory purchases while a significant decrease in demand could result in an increase in the amount of excess inventory quantities on hand requiring additional inventory write-downs.

**Allowance for Bad Debts:** The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. If the financial condition of the Company's customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowance may be required.

**Property, Plant and Equipment:** For financial statement purposes, the Company depreciates plant and equipment using the straight-line method over their estimated useful lives, which generally fall within the following ranges: buildings – 10 to 25 years; leasehold improvements – estimated useful life or remaining term of lease, whichever is shorter; machinery and equipment – 3 to 7 years. Certain tooling costs are capitalized and amortized over a 3 year life, while diminimus costs are expensed. For income tax purposes, the Company depreciates plant and equipment over their estimated useful lives using accelerated methods.

**Pension Plans:** The Company's funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds.

**Translation of Foreign Currencies:** The balance sheet accounts of non-U.S. operations, exclusive of stockholders' equity, are translated at year-end exchange rates, and income statement accounts are translated at weighted-average rates in effect during the year; any translation adjustments are made directly to a component of stockholders' equity.

**Intangible Assets:** In accordance with Statement of Financial Accounting Standards (SFAS) No. 121, *Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of*, and APB Opinion No. 17, *Intangible Assets*, the Company reviews long-lived assets and all intangible assets (including goodwill) for impairment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate, to the carrying amount including associated intangible assets of such operation. If the operation is determined to be unable to recover the carrying amount of its assets, then intangible assets are written down first, followed by the other long-lived assets of the operation, to fair value. Fair value is determined based on discounted cash flows or appraised values, depending upon the nature of the assets. (See Note 4 for further discussion of asset impairment charges.)

**Stock-Based Compensation:** In accordance with SFAS No. 123, *Accounting for Stock-Based Compensation*, the Company accounts for stock-based compensation at intrinsic value with disclosure of the effects of fair value accounting on net income and earnings per share on a pro forma basis.

**Cash Flows:** For purposes of the Consolidated Statements of Cash Flows, the Company considers all highly liquid instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash and cash equivalents approximates fair value due to the short maturities.

**Environmental Matters:** The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company's proportionate share of the amount can be reasonably estimated. Any recorded liabilities have not been discounted.

**Comprehensive Income:** The Company has adopted the provisions of SFAS No. 130, *Reporting Comprehensive Income*, which established standards for reporting and display of comprehensive income and its components. Comprehensive income is the total of net income and all other nonowner changes in stockholders' equity.

**Segments and Related Information:** The Company has adopted the provisions of SFAS No. 131, *Disclosures about Segments of an Enterprise and Related Information*. The statement established standards for the way that public business enterprises report information and operating segments in annual financial statements and requires reporting of selected information in interim financial reports.

**Derivative Instruments and Hedging:** The Financial Accounting Standards Board ("FASB") issued SFAS No. 137, *Accounting for Derivative Instruments and Hedging Activities – Deferral of the Effective Date of SFAS No. 133*, in June 1999. SFAS No. 133 was effective for all fiscal quarters of all fiscal years beginning after June 15, 2000. The statement requires companies to record derivatives on the balance sheet as assets or liabilities, measured at fair value. Gains or losses resulting from changes in the values of those derivatives would be accounted for depending on the use of the derivative and whether it qualifies for hedge accounting. The effect of the adoption of SFAS No. 133 as of January 1, 2001 was not material.

**Stock Splits:** Per share amounts and share data have been retroactively restated to give effect to the two-for-one stock split on June 1, 2001, effected in the form of a 100% stock dividend for holders of record as of May 15, 2001.

**Reclassifications:** Certain amounts from prior years have been reclassified to conform to the 2001 financial statement presentation.

# Notes to Financial Statements

continued

## Recently Issued Accounting Pronouncements

In June 2001, the FASB issued SFAS No. 141, *Business Combinations*, and SFAS No. 142, *Goodwill and Other Intangible Assets*. SFAS No. 141 requires all business combinations initiated after June 30, 2001 to be accounted for using the purchase method. Under SFAS No. 142, goodwill and intangible assets with indefinite lives are no longer amortized but are reviewed annually at a minimum for potential impairment by comparing the carrying value to the fair value of the reporting unit to which they are assigned. The provisions of SFAS No. 142 apply to goodwill and intangible assets arising from acquisitions completed subsequent to June 30, 2001. SFAS No. 142 is required to be adopted for goodwill and intangible assets arising from acquisitions prior to June 30, 2001 as of December 31, 2001. The Company is currently determining the impact of adopting this standard under the transition provisions of SFAS No. 142. Goodwill amortization expense for 2001 was \$26.2 million.

In June 2001, the FASB issued SFAS No. 143, *Accounting for Asset Retirement Obligations*. SFAS No. 143 addresses accounting and reporting for obligations associated with the retirement of tangible long-lived assets and the associated asset retirement costs. This statement is effective for fiscal years beginning after June 15, 2002. The Company is currently assessing the impact of this new standard.

In July 2001, the FASB issued SFAS No. 144, *Accounting for the Impairment or Disposal of Long-Lived Assets*, which is effective for fiscal years beginning after December 15, 2001. The provisions of this statement provide a single accounting model for determining impairment of long-lived assets. The Company is currently assessing the impact of this new standard.

## Note 2: Acquisitions and Divestitures

On November 13, 2001, the Company completed the acquisition of Packard BioScience Company (Packard) for consideration of approximately \$762 million in the form of approximately 22 million of the Company's common shares and the assumption of \$118 million in debt which was subsequently redeemed in March 2002 (see Note 14). Packard is a global developer, manufacturer and marketer of instruments and related consumables and services for use in drug discovery and other life sciences research and generated sales of approximately \$165 million for its fiscal year ended December 31, 2000.

Packard's operations, assumed as of the date of acquisition, are reported within the results from operations of the Life Sciences segment. The acquisition was accounted for as a purchase in accordance with the recently issued SFAS No. 141, and the Company has accordingly allocated the purchase price of Packard based upon the fair values of the net assets acquired and liabilities assumed. The allocation of the purchase price has not yet been finalized, however, the Company does not expect material changes. Portions of the net assets acquired and liabilities assumed were valued by independent appraisers utilizing customary valuation procedures and techniques. These intangible assets included \$69.0 million in acquired in-process research and development for projects that had not yet reached technological feasibility as of the acquisition date and for which no future alternative use existed. These costs were expensed during the fourth quarter of 2001. Other acquired intangible assets valued at \$237.3 million included the fair value of trade names, trademarks, patents and developed technology. Of this amount, \$76.5 million has been ascribed to trade names and trademarks for which an indefinite life has been assigned. The Packard acquisition also resulted in goodwill of \$438.6 million. Indefinite lived intangibles and goodwill are not being amortized in accordance with SFAS No. 141, effective for all business combinations completed subsequent to July 1, 2001.

In connection with this acquisition, the Company agreed to issue 0.311 shares of PerkinElmer common stock for each outstanding share of Packard common stock. The Company also agreed to assume all outstanding options to purchase Packard common stock, which became exercisable for shares of PerkinElmer common stock following the merger after giving effect to the same exchange ratio provided for in the merger agreement to the Packard common shareholders. The purchase price for Packard has been allocated to the estimated fair value of assets acquired and liabilities assumed. The preliminary purchase price allocation is based upon the Company's current estimates of respective fair values. Some allocations are based on studies and independent valuations, as discussed above.

The components of the estimated purchase price and preliminary allocation are as follows (in thousands):

Preliminary allocation of purchase price:

Stock issued to Packard shareholders	\$ 595,280
Debt assumed	118,432
Acquisition costs	20,261
Fair value of options exchanged	28,004
<b>Total consideration and acquisition costs</b>	<b>\$ 761,977</b>

Preliminary allocation of purchase price:

Current assets	157,677
Property, plant and equipment	23,186
Other assets	40,601
Identifiable intangible assets	237,320
In-process research and development	69,040
Goodwill	438,587
Liabilities assumed	(204,434)
	<b>\$ 761,977</b>

On July 31, 2000, the Company completed its acquisition of NEN Life Sciences, Inc. (NEN), a provider of state-of-the-art drug discovery products, services, reagents and technologies to the life sciences industry for an aggregate purchase price of approximately \$400 million. In connection with the acquisition, the Company paid approximately \$350 million in cash and issued warrants to purchase approximately 600,000 shares of the Company's common stock in exchange for all of the outstanding shares, options and warrants of NEN. In addition, the Company repaid approximately \$50 million of outstanding indebtedness of NEN. The Company financed the acquisition and repayment of the outstanding indebtedness with \$410 million of commercial paper borrowings with a weighted-average interest rate of 7%. These short-term borrowings were repaid in early August with proceeds from the issuance of long-term convertible debentures (see Note 14). NEN's operations, included in the consolidated results of the Company from the date of acquisition, are reported in the Life Sciences segment. The acquisition was accounted for as a purchase under APB Opinion No. 16, *Business Combinations* ("APB No. 16").

On May 28, 1999, the Company completed its acquisition of the Analytical Instruments Division (AI) of PE Corp. for an aggregate purchase price of approximately \$425 million, plus acquisition costs. The acquisition was accounted for as a purchase under APB No. 16.

Unaudited pro forma operating results for the Company, assuming the acquisition of AI occurred on December 29, 1997, NEN occurred on January 3, 1999, and Packard occurred on January 3, 2000 are as follows:

<i>(In thousands except per share data)</i>	2001	2000	1999
Sales from continuing operations	\$1,496,047	\$1,583,837	\$1,369,523
Income from continuing operations	59,160	53,031	(25,007)
Basic earnings per share	0.48	0.44	(0.27)
Diluted earnings per share	0.47	0.42	(0.27)
Net Income	\$ 94,285	\$ 84,279	\$ 122,398
Basic earnings per share	0.77	0.70	1.34
Diluted earning per share	0.74	0.67	1.31

# Notes to Financial Statements

continued

The pro forma amounts in the previous table exclude the in-process R&D charges of \$69.0 million, \$24.3 million and \$23 million for the Packard, NEN and AI acquisitions, respectively. The unaudited pro forma financial information is provided for informational purposes only and is not necessarily indicative of the Company's operating results that would have occurred had the acquisitions been consummated on the dates for which the consummation of the acquisitions are being given effect, nor is it necessarily indicative of the Company's future operating results. The pro forma amounts do not reflect any operating efficiencies and cost savings that the Company believes are achievable.

During the fourth quarter of 2001, the Company sold its IRAS business for cash of \$55.5 million, resulting in a pretax gain of approximately \$32.3 million. Additionally, the Company has deferred a gain of approximately \$3 million in connection with certain contingencies related to the sale. Also during the fourth quarter, the Company sold its Voltarc business for cash of \$9.5 million and a note for approximately \$8.0 million, resulting in a pretax loss of approximately \$6.3 million. The combined net income of the disposed businesses were \$5.4 million in 2000 and \$1.4 million in 2001 through the date of disposal.

During 2001, 2000 and 1999, in connection with the 1998 dispositions of the Company's Rotron and Sealol Industrial Seals divisions, the Company recognized approximately \$1.0 million, \$3.7 million and \$13.2 million, respectively, of pre-tax gains from the previously deferred sales proceeds as a result of the favorable resolution of certain events and contingencies. As of December 30, 2001, \$2.7 million in gains related to the Rotron sale remain deferred pending the resolution of certain matters.

During the fourth quarter of 2000, the Company sold its Berthold business at a net pre-tax gain of \$10 million. The Company deferred gain recognition of approximately \$11.9 million of sales proceeds from this divestiture in connection with certain contingencies related to the sale, \$2.0 million of which was recognized during 2001. Revenues for 2000 and 1999 for the divested business were \$30 million and \$38 million, respectively. Also during the fourth quarter of 2000, the Company recorded a pre-tax gain of \$16.7 million from the sale of a building. Additionally during 2001, the Company recognized \$2.4 million in net losses related to certain other dispositions.

During the first quarter of 2000, the Company sold its micromachined sensors and specialty semiconductor businesses for cash of \$24.3 million, resulting in a pre-tax gain of \$6.7 million. Combined financial results of the divested businesses for 2000 and 1999 were not material to the consolidated results of the Company.

All of the gains described above are reported on the "Gains on Dispositions, net" line in the consolidated income statements.

### Note 3: Restructuring and Integration Charges

During the fourth quarter of 2001, the Company expanded its continuing effort to restructure certain businesses to further improve performance. The plan resulted in additional pre-tax restructuring charges of \$9.2 million. The principal actions in these restructuring plans primarily relate to employee separation costs associated with the consolidation of certain European general and managerial functions within both the Life Sciences and Analytical Instruments segments, as well as costs associated with the closure of certain facilities and disposal of related assets.

	Employee Separation Costs	Disposal of Certain Product Lines and Assets	Termination of Leases and Other Contractual Obligations	Total
2001 Plan:				
Life Sciences	\$ 3.2	\$0.1	\$0.6	\$ 3.9
Analytical Instruments	3.8	—	1.5	5.3
Total restructuring charges	7.0	0.1	2.1	9.2
Amounts incurred during 2001	(1.6)	—	—	(1.6)
Accrued restructuring costs at December 30, 2001	\$ 5.4	\$0.1	\$2.1	\$ 7.6

During the fourth quarter of 2000, the Company recorded a pre-tax restructuring charge of \$15.1 million for actions to be completed in 2001 (the "2000 plan"). These charges related to the Company's Life Sciences and Optoelectronics segments. The principal actions in the restructuring plans included close-down or consolidation of a number of offices and facilities, the closure of certain manufacturing facilities, and the disposal of underutilized assets. The restructuring charges were broken down as follows by operating segment: The Life Sciences' actions were associated with rationalization of its distribution network and overall facility consolidation. The Optoelectronics' actions were associated with its Lighting and Imaging businesses and relate to employee separation costs and the closures of certain manufacturing facilities. During 2001, the Company provided for an additional \$0.8 million under the 2000 plan as a result of additional needs related to lease terminations. Also during 2001, due to the substantial completion of the actions of the 2000 plan, the Company reevaluated its 2000 restructuring plans. As a result of this review, costs associated with the previous Life Sciences plan related to the rationalization of its network and facility consolidation were no longer required. As a result, the Company recognized a restructuring credit of \$0.5 million during 2001.

The following table summarizes activity related to the 2000 plan:

	Employee Separation Costs	Disposal of Certain Product Lines and Assets	Termination of Leases and Other Contractual Obligations	Total
Total restructuring charges	\$10.1	\$ 2.9	\$ 2.1	\$ 15.1
Amounts incurred during 2000	—	—	—	—
Accrued restructuring costs at December 31, 2000	10.1	2.9	2.1	15.1
Additional amounts provided during 2001	—	—	0.8	0.8
Amounts incurred during 2001	(9.6)	(2.9)	(2.9)	(15.4)
Amounts reversed during 2001	(0.5)	—	—	(0.5)
Accrued restructuring costs at December 30, 2001	\$ —	\$ —	\$ —	\$ —

Also during 2000, as a result of the substantial completion of previously announced restructuring plans, the Company recognized restructuring credits of \$11.2 million relating to 1999 and prior restructuring plans.

As part of the Packard acquisition, the Company recorded approximately \$33.0 million in integration charges. The integration plans include initiatives to integrate the operations of Packard and the Company and are principally comprised of amounts related to employee separation costs and the termination of leases and other contractual obligations.

	Employee Separation Costs	Disposal of Certain Product Lines and Assets	Termination of Leases and Other Contractual Obligations	Total
Packard Plan	\$20.0	\$3.0	\$10.0	\$33.0

During the second quarter of 2000, the Company finalized its restructuring plan for AI. Based on continued aggressive actions by the Company to improve the cost structure of the acquired business, and increased costs related primarily to employment integration, the Company increased its original estimate of restructuring costs recorded at the acquisition date by \$24.0 million in connection with purchase accounting. All restructuring actions will have been completed by the first quarter of 2002.

As part of the July 2000 acquisition of NEN, the Company recorded a \$4.0 million restructuring charge for actions targeted at reduced employment costs, consolidation of certain facilities and the termination of certain leases and other contractual obligations.

# Notes to Financial Statements

continued

The following table summarizes reserve activity during fiscal 2001 related to the AI and NEN acquisitions as discussed above:

Totaling restructuring charges	\$ 42.1
Amounts incurred during 2000	(9.8)
Accrued restructuring costs at December 31, 2000	32.3
Amounts incurred during 2001	(23.1)
Accrued restructuring costs at December 30, 2001	\$ 9.2

Cash outlays during 2001 were approximately \$36.3 million for the above discussed plans. The Company expects to incur approximately \$40-50 million of cash outlays in connection with these plans during 2002.

## Note 4: Asset Impairment Charges

During the third quarter of 1999, in connection with its ongoing review of its portfolio of businesses, the Company conducted a strategic review of certain units within its business segments. The strategic review triggered an impairment review of long-lived assets of certain business units that were expected to be disposed. The Company calculated the present value of expected cash flows of certain business units to determine the fair value of those assets. Accordingly, in the third quarter of 1999, the Company recorded non-cash impairment charges and wrote down goodwill by \$15 million in the Instruments segment and \$3 million in the Optoelectronics segment. Sales and operating profit for the businesses under strategic review were approximately \$54 million and \$2 million, respectively, in 1999.

## Note 5: Other Expense

Other expense, net consisted of the following:

<i>(In thousands)</i>	2001	2000	1999
Interest income	\$ 3,724	\$ 3,844	\$ 3,020
Interest expense	(39,065)	(36,745)	(24,704)
Gains on sale of investments, net	4,274	1,294	1,952
Other	1,272	(2,085)	4,724
	\$ (29,795)	\$ (33,692)	\$ (15,008)

The increase in interest expense in 2001 was due to the impact of higher debt levels resulting from acquisitions. The increase in gains on sales of investments, net was due to the disposal of two non-strategic investments during 2001 for gains of approximately \$3.4 million and \$0.9 million, respectively.

## Note 6: Income Taxes

The components of income from continuing operations before income taxes for financial reporting purposes were as follows:

<i>(In thousands)</i>	2001	2000	1999
U.S.	\$(84,308)	\$(11,325)	\$(28,342)
Non-U.S.	118,462	110,302	39,838
	\$ 34,154	\$ 98,977	\$ 11,496

The components of the provision for income taxes for continuing operations were as follows:

<i>(In thousands)</i>	Current	Deferred (Prepaid)	Total
<b>2001</b>			
Federal	\$ (5,669)	\$ 5,899	\$ 230
State	(231)	2,828	2,597
Non-U.S.	30,744	1,203	31,947
	<b>\$24,844</b>	<b>\$ 9,930</b>	<b>\$34,774</b>
<b>2000</b>			
Federal	\$ 1,314	\$ 11,561	\$12,875
State	504	2,380	2,884
Non-U.S.	25,257	(1,317)	23,940
	<b>\$27,075</b>	<b>\$ 12,624</b>	<b>\$39,699</b>
<b>1999</b>			
Federal	\$ 6,511	\$(12,706)	\$ (6,195)
State	330	(1,970)	(1,640)
Non-U.S.	13,234	(814)	12,420
	<b>\$20,075</b>	<b>\$(15,490)</b>	<b>\$ 4,585</b>

The total provision for income taxes included in the consolidated financial statements was as follows:

<i>(In thousands)</i>	<b>2001</b>	2000	1999
Continuing operations	\$34,774	\$ 39,699	\$ 4,585
Discontinued operations	21,858	21,570	92,436
	<b>\$56,632</b>	<b>\$ 61,269</b>	<b>\$97,021</b>

The major differences between the Company's effective tax rate for continuing operations and the federal statutory rate were as follows:

	<b>2001</b>	2000	1999
Federal statutory rate	35.0%	35.0%	35.0%
Non-U.S. rate differential, net	(26.4)	(18.7)	(23.4)
State income taxes, net	4.9	2.0	(6.2)
Goodwill amortization	21.2	12.0	29.7
Goodwill write-downs	0.0	0.0	45.6
In-process R&D	70.8	11.5	0.0
Change in valuation allowance	(1.5)	(2.5)	35.1
Other, net	(2.2)	0.8	(75.9)
Effective tax rate	<b>101.8%</b>	<b>40.1%</b>	<b>39.9%</b>

The 2001 tax provision and effective tax rate for continuing operations was impacted by the inclusion of in-process research and development charges associated with the Packard acquisition and the disposals of the Voltarc and the IRAS businesses.

## Notes to Financial Statements

continued

The 2000 tax provision and effective rate for continuing operations includes tax for nonrecurring items such as the disposals of the Berthold, micromachined sensors and specialty semiconductor businesses. The 1999 tax provision and effective rate for continuing operations was impacted by a non-deductible goodwill write-down.

The tax effects of temporary differences and carryovers that gave rise to deferred income tax assets and liabilities as of December 30, 2001 and December 31, 2000 were as follows:

<i>(In thousands)</i>	2001	2000
Deferred tax assets:		
Inventory reserves	\$ 5,834	\$ 149
Other reserves	12,606	17,300
Deferred income	1,152	6,179
Vacation pay	3,208	4,991
Net operating loss carry forwards	23,565	14,447
Post-retirement health benefits	4,699	5,191
Restructuring reserve	16,784	15,995
In-process R&D	9,916	10,726
All other, net	46,952	45,806
Total deferred tax assets	124,716	120,784
Deferred tax liabilities:		
Pension contribution	(11,477)	(11,912)
Amortization	(97,428)	(5,877)
Depreciation	(20,196)	(26,467)
All other, net	(5,440)	(16,081)
Total deferred tax liabilities	(134,541)	(60,337)
Valuation allowance	(13,435)	(14,447)
Net prepaid taxes	\$ (23,260)	\$ 46,000

At December 30, 2001, the Company had non-U.S. (primarily from Germany) net operating loss carryovers of \$13.4 million, substantially all of which carry forward indefinitely. The valuation allowance results primarily from these carryovers, as the Company expects that they will not be realized.

Current deferred tax assets of \$78 million and \$53 million were included in other current assets at December 30, 2001 and December 31, 2000, respectively. Long-term deferred tax liabilities of \$101 million and \$8 million were included in long-term liabilities at December 30, 2001 and December 31, 2000, respectively.

In general, it is the practice and intention of the Company to reinvest the earnings of its non-U.S. subsidiaries in those operations. Repatriation of retained earnings is done only when it is advantageous. Applicable federal taxes are provided only on amounts planned to be remitted.

During 2001 the Company received notice from the Internal Revenue Service (IRS) that a previously brought US Tax Court case had been settled in the Company's favor, resulting in a minor refund. The total additional tax proposed by the IRS previously amounted to approximately \$74 million plus interest.

## Note 7: Discontinued Operations

In July 2001, the Company approved a plan to sell its Security and Detection Systems business. The results of operations of the Security and Detection Systems business were previously reported as part of the Analytical Instruments business. In October 2001, the Company approved a plan to sell its Fluid Sciences business. The Company has accounted for the plan to sell both businesses as discontinued operations in accordance with APB No. 30, and accordingly, the results of operations of the Security and Detection Systems business and the Fluid Sciences business have been segregated from continuing operations and reported as a separate line on the Company's Consolidated Income Statements. The Company does not expect to incur a loss on the sale of either business.

On August 20, 1999, the Company sold the assets of its Technical Services business, including the outstanding capital stock of EG&G Defense Materials, Inc., a subsidiary of the Company, to EG&G Technical Services, Inc. The results of operations of the Technical Services business were previously reported as one of five business segments of the Company. The Company accounted for the sale of its Technical Services business as a discontinued operation in accordance with APB No. 30 and, accordingly, the results of operations of the Technical Services business have been segregated from continuing operations and reported as a separate line item on the Company's Consolidated Income Statements during 1999. The Company recorded a pre-tax gain on disposition of discontinued operations of \$181 million, net of transaction and related costs, during 1999. The \$110 million after-tax gain was reported separately from the results of the Company's continuing operations.

Summary operating results of the discontinued operations of the Technical Services, Fluid Sciences and Security and Detection Systems businesses (through December 30, 2001) were as follows:

<i>(In thousands)</i>	2001	2000	1999
Sales	\$271,709	\$359,735	\$615,070
Costs and expenses	213,139	305,829	546,454
Operating income from discontinued operations	58,570	53,906	68,616
Other expense	(5,487)	(8,394)	(9,560)
Income from discontinued operations before income taxes	53,083	45,512	59,056
Provision for income taxes	20,325	18,723	21,931
Income from discontinued operations, net of income taxes	\$ 32,758	\$ 26,789	\$ 37,125

## Note 8: Earnings per Share

Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the year. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common shares outstanding, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations:

<i>(In thousands)</i>	2001	2000	1999
Number of common shares – basic	103,687	98,212	91,044
Effect of dilutive securities			
Stock options	—	4,022	2,030
Other	—	44	64
Number of common shares – diluted	103,687	102,278	93,138

Potential common shares of 3,570,000 were not included in the computation of weighted-average diluted shares outstanding for 2001 because their inclusion would be anti-dilutive.

# Notes to Financial Statements

continued

Options to purchase 8,044,000 and 54,400 shares of common stock were not included in the computation of diluted earnings per share for 2001 and 2000, respectively, because the options' exercise prices were greater than the average market price of the common shares and thus their effect would have been antidilutive. Additionally, the Company's zero coupon senior convertible debentures (see Note 14) are currently convertible into 10.8 million shares of the Company's common stock at approximately \$44.00 per share. Conversion of the debentures was not assumed in the computation of diluted earnings per share because the effect of assumed conversion would have been antidilutive.

## Note 9: Accounts Receivable

Accounts receivable were net of reserves for doubtful accounts of \$13.1 million and \$13.3 million as of December 30, 2001 and December 31, 2000 respectively.

During 2001, the Company established a wholly owned consolidated subsidiary to purchase, on a revolving basis, certain of the Company's accounts receivable balances and simultaneously sell an undivided interest in this pool of receivables to a financial institution. As collections reduce the accounts receivable balances, new receivables are sold. The Company's consolidated subsidiary retains the risk of credit loss on the receivables and accordingly, the full amount of the allowance for doubtful accounts has been provided for on the Company's balance sheet. Under the terms of this arrangement, the Company retains collection and administrative responsibilities for the balances. The facility is renewable on an annual basis and has an effective interest rate of approximately LIBOR plus 30 basis points. Amounts sold under this facility during 2001 approximated \$37 million. This amount has reduced the outstanding receivable balance.

## Note 10: Inventories

Inventories as of December 30, 2001 and December 31, 2000 consisted of the following:

<i>(in thousands)</i>	2001	2000
Raw materials	\$ 66,793	\$ 61,564
Work in progress	59,160	46,785
Finished goods	116,518	82,177
	<u>\$242,471</u>	<u>\$190,526</u>

The increase in inventory is primarily attributable to the Packard acquisition which occurred during the fourth quarter of 2001.

## Note 11: Property, Plant and Equipment

Property, plant and equipment, at cost, as of December 30, 2001 and December 31, 2000 consisted of the following:

<i>(in thousands)</i>	2001	2000
Land	\$ 24,725	\$ 23,767
Building and leasehold improvements	130,541	125,830
Machinery and equipment	272,505	274,544
	<u>\$427,771</u>	<u>\$424,141</u>

Increases in property, plant and equipment are primarily due to the acquisition of Packard and capital expenditures related to the Analytical Instruments facility in Shelton, CT during 2001, offset to some extent by the sale-leaseback of certain facilities and equipment, as previously discussed.

## Note 12: Investments

Investments as of December 30, 2001 and December 31, 2000 consisted of the following:

<i>(In thousands)</i>	2001	2000
Marketable investments	\$15,716	\$21,936
Joint venture and other investments	13,897	14,290
	<u>\$29,613</u>	<u>\$36,226</u>

The decrease in marketable investments from 2000 to 2001 resulted mainly from the sale of approximately 70% of the Company's investment in Genomic Solutions, Inc. Marketable investments consist of trust assets which are carried at market value and primarily reflect equity and fixed-income securities held to meet obligations associated with the supplemental executive retirement plan. As of December 30, 2001, the fixed-income securities held within marketable investments had, on average, maturities of between 3 and 30 years.

The change in the joint venture and other investments balance from 2000 to 2001 is reflective of the Company's sale of its interest in a joint venture with Seiko in connection with the sale of the IRAS business, offset by an additional \$3.1 million investment in Bragg Photonics. This additional investment brings the Company's total investment in Bragg Photonics to 31%. The Company recognized a \$1.9 million loss in 2001 as a result of equity accounting for this investment. Joint venture investments reflect holdings the Company maintains which are accounted for under the equity method of accounting.

The net unrealized holding gain (loss) on marketable investments, net of deferred income taxes, reported as a component of accumulated other comprehensive income (loss) in stockholders' equity, was a \$1.4 million loss and a \$0.9 million gain at December 30, 2001 and December 31, 2000, respectively.

Marketable investments classified as available for sale as of December 30, 2001 and December 31, 2000 consisted of the following:

	Market Value	Gross Unrealized Holding		
		Cost	Gains	(Losses)
2001				
Common stocks	\$ 8,865	\$10,864	\$ 32	\$(2,031)
Fixed-income security	6,098	6,066	32	—
Other	753	766	—	(13)
	<u>\$15,716</u>	<u>\$17,696</u>	<u>\$ 64</u>	<u>\$(2,044)</u>
2000				
Common stocks	\$17,356	\$16,021	\$1,689	\$ (354)
Fixed-income security	4,143	4,074	69	—
Other	437	492	—	(55)
	<u>\$21,936</u>	<u>\$20,587</u>	<u>\$1,758</u>	<u>\$ (409)</u>

## Note 13: Intangible Assets

Intangible assets consist mainly of goodwill from acquisitions accounted for using the purchase method of accounting, representing the excess of cost over the fair market value of the net assets of the acquired businesses. Goodwill, net of accumulated amortization, was \$1,034 million and \$631 million at December 30, 2001 and December 31, 2000, respectively. Other identifiable intangible assets from acquisitions include patents, trademarks, trade names and developed technology and are being amortized over periods of 10-40 years.

# Notes to Financial Statements

continued

Other identifiable intangible assets, net of accumulated amortization, were \$497 million and \$256 million at December 30, 2001 and December 31, 2000, respectively. Intangible assets as of December 30, 2001 and December 31, 2000 consisted of the following:

<i>(In thousands)</i>	2001	2000
Goodwill	\$ 1,105,247	\$ 677,029
Other identifiable intangible assets	526,759	293,900
	1,632,006	970,929
Less: accumulated amortization	(101,398)	(84,360)
	\$ 1,530,608	\$ 886,569

As previously discussed, the issuance of SFAS No. 142 will result in the discontinuance of goodwill and indefinite lived intangible amortization from December 31, 2001 forward. Instead, these items will be tested on an annual basis for potential impairment by comparing the carrying value to the fair value of the reporting unit to which they are assigned.

The increase in intangible assets resulted primarily from the acquisition of Packard in 2001, as previously discussed.

## Note 14: Debt

Short-term debt at December 30, 2001 was \$125.7 million with no commercial paper outstanding. Short-term debt at December 31, 2000 was \$183.1 million and was comprised primarily of commercial paper borrowings. The weighted average interest rate on the commercial paper borrowings was 4.4% and 6.7%, during 2001 and 2000, respectively. Weighted average maturities were 20 days or less during 2001 and 60 days or less during 2000.

In March 2002, the Company's revolving credit facility was refinanced in the amount of \$270 million and will expire in March 2003. The Company refinanced a \$100 million revolving credit facility, which expires in March 2006. These agreements, which serve as backup facilities for the commercial paper borrowings, have no significant commitment fees. Under the terms of the credit agreement, the Company is required to maintain certain minimum Debt to Total Capital and Interest Coverage ratios, with which the Company was in compliance during all of 2000 and 2001. There were no amounts outstanding under these lines at December 30, 2001 or December 31, 2000 nor at any time during these two years.

At December 30, 2001 and December 31, 2000, long-term debt was \$598.1 million and \$583.3 million, respectively. Included in these amounts are \$115 million of unsecured ten-year notes issued in October 1995, which carry an interest rate of 6.8% and mature in 2005. During the fourth quarter of 2001, this fixed rate was swapped to a floating rate, resulting in an all-in cost of funds of 4.46% during 2001, an annualized reduction of 2.34% from the fixed rate. This interest rate swap instrument resets semi-annually in arrears based upon six month USD LIBOR. The fair value of this instrument as of December 30, 2001 was \$(2.3) million, which is offset by a corresponding gain in the underlying bond. Other long term debt includes zero coupon senior convertible debentures described below which had a \$483 million accreted value at 2001 and a \$468 million accreted value at 2000. The carrying amount of the unsecured ten-year notes and senior subordinated ten-year notes approximated the estimated fair value at December 30, 2001, based on a quoted market price. The estimated fair value of the convertible debentures approximated \$512 million at December 30, 2001, also based on a quoted market price.

In August 2000, the Company sold zero coupon senior convertible debentures with an aggregate purchase price of \$460 million. The Company used the offering's net proceeds of approximately \$448 million to repay a portion of its commercial paper borrowings, which had been increased temporarily to finance the NEN acquisition. Deferred issuance costs of \$12 million were recorded as a noncurrent asset and are being amortized over three years. The debentures, which were offered by a prospectus supplement pursuant to the Company's effective shelf registration statement, are due August 2020, and were priced with a yield to maturity of 3.5%. At maturity, the Company is required to repay \$921 million, comprised of \$460 million of original purchase price plus accrued original issue discount. The Company

may redeem some or all of the debentures at any time on or after August 7, 2003 at a redemption price equal to the issue price plus the accrued original issue discount through the redemption date. Holders of the debentures may require the Company to repurchase some or all of the debentures in August 2003 and August 2010, or at any time when there is a change in control of the Company, as is customary and ordinary for debentures of this nature, at a repurchase price equal to the initial price to the public plus the accrued original issue discount through the date of the repurchase. The debentures are currently convertible into 10.8 million shares of the Company's common stock at approximately \$44.00 per share.

In November 2001, the Company completed its acquisition of Packard BioScience Company and assumed \$118 million of senior subordinated ten-year notes issued in March 1997 at an interest rate of 9.375%. The Company has elected to redeem the notes on March 1, 2002 at a rate of 104.688% in accordance with the indenture dated as of March 4, 1997. As such, this amount has been reclassified to short-term debt for presentation purposes.

### Note 15: Accrued Expenses

Accrued expenses as of December 30, 2001 and December 31, 2000 consisted of the following:

<i>(In thousands)</i>	2001	2000
Payroll and incentives	\$ 34,714	\$ 34,498
Employee benefits	47,093	42,126
Federal, non-U.S. and state income taxes	83,504	39,973
Other accrued operating expenses	224,018	180,299
	<b>\$389,329</b>	<b>\$296,896</b>

The increase in accrued expenses is due primarily to accrued expenses assumed as part of the Packard acquisition.

### Note 16: Employee Benefit Plans

Except where noted otherwise, the following employee benefit plan disclosures include amounts and information, on a combined basis, for both the continuing and discontinued operations of the Company.

**Savings Plan:** The Company has a savings plan for the benefit of qualified U.S. employees. Under this plan, for all business units except those within Life Sciences, the Company contributes an amount equal to the lesser of 55% of the amount of the employee's voluntary contribution or 3.3% of the employee's annual compensation. For Life Sciences, the Company contributes an amount equal to the lesser of 100% of the employee's voluntary contribution or 5.0% of the employee's annual compensation. Savings plan expense charged to continuing operations was \$5.8 million in 2001, \$4.2 million in 2000, and \$2.8 million in 1999.

**Pension Plans:** The Company has defined benefit pension plans covering substantially all U.S. employees except those employed by Life Sciences and non-U.S. pension plans for non-U.S. employees. The U.S. defined benefit pension plans were closed to new hires effective January 31, 2001. The plans provide benefits that are based on an employee's years of service and compensation near retirement. Assets of the U.S. plan are comprised primarily of equity and debt securities.

Net periodic pension cost included the following components:

<i>(In thousands)</i>	2001	2000	1999
Service cost	\$ 6,860	\$ 7,830	\$ 9,707
Interest cost	19,011	19,315	20,917
Expected return on plan assets	(23,235)	(20,588)	(24,675)
Net amortization and deferral	(460)	(486)	(645)
	<b>\$ 2,176</b>	<b>\$ 6,071</b>	<b>\$ 5,304</b>

# Notes to Financial Statements

continued

The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company's consolidated balance sheets as of December 30, 2001 and December 31, 2000.

<i>(In thousands)</i>	2001		2000	
	Non-U.S.	U.S.	Non-U.S.	U.S.
Actuarial present value of benefit obligations:				
Accumulated benefit obligations	\$111,610	\$157,573	\$112,940	\$162,809
Projected benefit obligations at beginning of year	\$123,386	\$174,351	\$141,552	\$171,106
Service cost	2,020	4,840	3,206	4,624
Interest cost	7,054	11,957	7,119	12,196
Benefits paid and plan expenses	(5,535)	(13,077)	(5,607)	(9,677)
Participants' contributions	540	—	194	—
Actuarial loss (gain)	4,616	(9,974)	(12,831)	(3,898)
Plan Amendments	—	(861)	—	—
Effect of exchange rate changes	(6,778)	—	(10,210)	—
Dispositions	—	—	(17,584)	—
Curtailment gain – discontinued operations	(2,672)	—	—	—
Acquisitions	2,229	—	17,547	—
Projected benefit obligations at end of year	124,860	167,236	123,386	174,351
Fair value of plan assets at beginning of year	48,737	230,347	35,560	254,535
Actual return on plan assets	(5,228)	(8,685)	4,067	(14,038)
Benefits paid and plan expenses	(5,535)	(13,077)	(5,607)	(9,677)
Employer contribution	5,133	—	4,437	—
Participant contribution	540	—	194	—
Effect of exchange rate changes	(1,700)	—	(2,841)	—
Transfer out – discontinued operations	—	—	12,927	(473)
Fair value of plan assets at end of year	41,947	208,585	48,737	230,347
Plan assets less (greater) than projected benefit obligations	82,913	(41,349)	74,649	(55,996)
Unrecognized net transition asset (obligation)	(277)	—	(322)	512
Unrecognized net prior service costs	(379)	623	(410)	(52)
Unrecognized net gain (loss)	1,184	1,428	7,441	19,469
Accrued pension liability (asset)	\$ 83,441	\$ (39,298)	\$ 81,358	\$ (36,067)
Additional minimum liability	189	—	257	—
Intangible asset	(189)	—	(257)	—
Net asset/liability	\$ 83,441	\$ (39,298)	\$ 81,358	\$ (36,067)
Actuarial assumptions as of the year-end measurement date:				
Discount rate	5.7%	7.5%	6.0%	7.5%
Rate of compensation increase	3.4%	4.5%	3.4%	4.5%
Expected rate of return on assets	7.9%	9.0%	7.9%	9.0%

Non-U.S. accrued pension liabilities classified as long-term liabilities totaled \$80 million and \$86 million as of December 30, 2001 and December 31, 2000, respectively. The U.S. pension asset was classified as other noncurrent assets.

The Company also sponsors a supplemental executive retirement plan to provide senior management with benefits in excess of normal pension benefits. Effective July 31, 2000, this plan was closed to new entrants. At December 30, 2001 and December 31, 2000, the projected benefit obligations were \$16.5 million and \$16.4 million, respectively. Assets with a fair value of \$8.0 million and \$9.2 million segregated in a trust, were available to meet this obligation as of December 30, 2001 and December 31, 2000, respectively. Pension expense for this plan was approximately \$1.1 million in 2001, \$2.0 million in 2000 and \$1.8 million in 1999.

**Postretirement Medical Plans:** The Company provides health care benefits for eligible retired U.S. employees under a comprehensive major medical plan or under health maintenance organizations where available. The majority of the Company's U.S. employees become eligible for retiree health benefits if they retire directly from the Company and have at least ten years of service. Generally, the major medical plan pays stated percentages of covered expenses after a deductible is met and takes into consideration payments by other group coverages and by Medicare. The plan requires retiree contributions under most circumstances and has provisions for cost-sharing charges. Effective January 1, 2000, this plan was closed to new hires. For employees retiring after 1991, the Company has capped its medical premium contribution based on employees' years of service. The Company funds the amount allowable under a 401(h) provision in the Company's defined benefit pension plan. Assets of the plan are comprised primarily of equity and debt securities.

Net periodic post-retirement medical benefit cost (credit) included the following components:

<i>(in thousands)</i>	<b>2001</b>	2000	1999
Service cost	\$ 207	\$ 232	\$ 289
Interest cost	646	992	1,036
Expected return on plan assets	(1,062)	(1,219)	(1,304)
Net amortization and deferral	(674)	(1,516)	(1,022)
	<b>\$ (883)</b>	<b>\$(1,511)</b>	<b>\$(1,001)</b>

# Notes to Financial Statements

continued

The following table sets forth the changes in the postretirement medical plan's funded status and the amounts recognized in the Company's consolidated balance sheets at December 30, 2001 and December 31, 2000.

<i>(in thousands)</i>	2001	2000
Actuarial present value of benefit obligations:		
Retirees	\$10,651	\$10,379
Active employees eligible to retire	400	371
Other active employees	2,804	2,117
Accumulated benefit obligations at beginning of year	13,855	12,867
Service cost	207	232
Interest cost	646	992
Benefits paid	(905)	(1,196)
Actuarial loss	1,315	430
Plan adjustments	(6,109)	530
Curtailment gain - discontinued operations	(115)	—
Change in accumulated benefit obligations during the year	(4,961)	988
Retirees	5,720	10,651
Active employees eligible to retire	422	400
Other active employees	2,752	2,804
Accumulated benefit obligations at end of year	8,894	13,855
Fair value of plan assets at beginning of year	12,254	14,474
Actual return on plan assets	(422)	(590)
Benefits paid and plan expenses	(1,377)	(1,630)
Fair value of plan assets at end of year	10,455	12,254
Fair value of plan assets (greater) less than accumulated benefit obligations	(1,561)	1,601
Unrecognized prior service costs	4,705	(489)
Unrecognized net gain	2,347	4,614
Accrued post-retirement medical liability	\$ 5,491	\$ 5,726
Actuarial assumptions as of the year-end measurement date		
Discount rate	7.5%	7.5%
Expected rate of return on assets	9.0%	9.0%
Healthcare cost trend rate:		
First year	N/A	8.0%
Ultimate	N/A	5.5%
Time to reach ultimate	N/A	3 years

The accrued postretirement medical liability included \$4.5 million and \$4.7 million classified as long-term liabilities as of December 30, 2001 and December 31, 2000, respectively.

*Deferred Compensation Plans:* During 1998, the Company implemented certain nonqualified deferred compensation programs that provide benefits payable to officers and certain key employees or their designated beneficiaries at specified future dates, upon retirement or death. Benefit payments under these plans are funded by a combination of contributions from participants and the Company. In 2000, this plan was extended to cover members of the Board of Directors.

*Employee Stock Purchase Plan:* The Company has an Employee Stock Purchase Plan, whereby participating employees have the right to purchase common stock at a price equal to 85% of the lower of the closing price on the first day or the last day of the six-month offering period. The number of shares which an employee may purchase, subject to certain aggregate limits, is determined by the employee's voluntary contribution which may not exceed 10% of base compensation.

*Other:* The Company has granted restricted stock awards to certain executive employees and directors which contain vesting provisions tied to certain Company performance metrics. The shares available under these awards are a component of the Company's 1999 Incentive Plan.

#### **Note 17: Commitments and Contingencies**

The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Each of these matters is subject to various uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company. The Company has established accruals for matters that are probable and reasonably estimable. Management believes that any liability that may ultimately result from the resolution of these matters in excess of amounts provided will not have a material adverse effect on the financial position or results of operations of the Company.

In addition, the Company is conducting a number of environmental investigations and remedial actions at current and former Company locations and, along with other companies, has been named a potentially responsible party (PRP) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company's responsibility is established and when the cost can be reasonably estimated. The Company has accrued \$6.9 million as of December 30, 2001, representing management's estimate of the total cost of ultimate disposition of known environmental matters. Such amount is not discounted and does not reflect the recovery of any amounts through insurance or indemnification arrangements. These cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the timeframe over which remediation may occur and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that such accrued amounts could be paid out over a period of up to five years. As assessments and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had or are expected to have a material effect on the Company's financial position or results of operations. While it is reasonably possible that a material loss exceeding the amounts recorded may have been incurred, the preliminary stages of the investigations make it impossible for the Company to reasonably estimate the range of potential exposure.

Included in the lease commitments discussed in Note 21 to the Financial Statements is a six-year operating lease agreement signed in 2000 for a facility in the Optoelectronics segment. At the end of the lease term, the Company, at its option, may: (i) renew the lease; (ii) purchase the property at a price equal to the lessor's original cost (approximately \$30 million); or (iii) allow the lease to expire and cause the property to be sold. The Company's ability to cause the property to be sold depends upon its compliance with certain terms of the lease. Under certain conditions, the Company would receive any excess of the net sales proceeds over the property's original cost. In the event that the net sales proceeds are less than the original cost, the Company would make certain contingent rental payments to the lessor equal to that difference, subject to a maximum amount.

# Notes to Financial Statements

continued

## Note 18: Risks and Uncertainties

For information concerning various investigations, claims, legal proceedings, environmental investigations and remedial actions, see Note 17. For information concerning factors affecting future performance, see Management's Discussion and Analysis.

Costs incurred under cost-reimbursable government contracts, primarily in the former Technical Services segment, which is presented as discontinued operations, are subject to audit by the government. The results of prior audits, completed through 1997, have not had a material effect on the Company.

The Company's management and operations contracts with the DOE are presented as discontinued operations. The Company's last DOE management and operations contract expired on September 30, 1997. The Company is in the process of negotiating contract closeouts and does not anticipate incurring any material loss in excess of previously established reserves.

## Note 19: Stockholders' Equity

**Stock-Based Compensation:** Under the 2001 Incentive Plan, 8.8 million additional shares of the Company's common stock were made available for option grants, restricted stock awards, performance units and other stock-based awards. Under the 1999 Incentive Plan, 7.0 million additional shares of the Company's common stock were made available for similar stock-based awards. At December 30, 2001, 3.6 million shares of the Company's common stock were reserved for employee benefit plans.

The Company has nonqualified and incentive stock option plans for officers and key employees. Under these plans, options may be granted at prices not less than 100% of the fair market value on the date of grant. Options expire 7-10 years from the date of grant, and options granted become exercisable, in ratable installments, over periods of 3-5 years from the date of grant. The Compensation Committee of the Board of Directors, at its sole discretion, may also include stock appreciation rights in any option granted. There are no stock appreciation rights outstanding under these plans.

The following table summarizes stock option activity for the three years ended December 30, 2001:

	2001		2000		1999	
	Number of Shares	Weighted-Average Price	Number of Shares	Weighted-Average Price	Number of Shares	Weighted-Average Price
<i>(Shares in thousands)</i>						
Outstanding at beginning of year	9,650	\$19.52	9,144	\$11.77	6,600	\$10.03
Granted	9,315	30.31	5,564	25.39	5,422	12.97
Exercised	(2,073)	12.41	(3,724)	10.12	(2,218)	9.54
Lapsed	(907)	28.85	(1,334)	15.51	(660)	11.64
Outstanding at end of year	15,985	26.25	9,650	19.52	9,144	11.77
Exercisable at end of year	5,567	17.43	2,490	12.71	3,702	9.66

The following table summarizes information about stock options outstanding at December 30, 2001:

Actual Range of Exercise Prices 150% Increment	Options Outstanding		Options Exercisable		
	Number Outstanding at December 30, 2001	Weighted-Average Remaining Contractual Life	Weighted-Average Exercise Price	Number Exercisable at December 30, 2001	Weighted-Average Exercise Price
\$ 1.56 – 1.57	3,860	2.0	\$ 1.56	3,860	\$ 1.56
\$ 3.11 – 4.23	92,384	3.0	\$ 4.08	92,384	\$ 4.08
\$ 4.67 – 5.28	30,249	3.9	\$ 4.68	30,249	\$ 4.68
\$ 7.04 – 10.16	795,594	4.7	\$ 8.64	711,934	\$ 8.52
\$10.77 – 16.00	2,955,190	6.0	\$13.85	2,187,126	\$13.77
\$16.59 – 24.15	3,081,083	6.6	\$19.81	1,921,203	\$19.79
\$25.05 – 37.17	6,806,840	6.3	\$30.42	407,574	\$29.36
\$37.98 – 56.59	2,168,844	6.5	\$46.19	179,649	\$46.75
\$57.22 – 67.92	51,248	7.7	\$58.32	32,584	\$58.32
\$ 1.56 – 67.92	15,985,292	6.2	\$26.25	5,566,563	\$17.43

During 2001, approximately 6,071,000 and 1,190,000 options were granted pursuant to the 2001 Incentive Plan and the 1999 Incentive Plan, respectively, at exercise prices ranging from \$23.84 per share to \$50.28 per share. The remaining options granted during 2001 were done so principally under plans associated with Packard. At December 30, 2001, there were 3,491,000 common shares available for grant under active equity plans.

The weighted-average fair values of options granted during 2001, 2000 and 1999 were \$14.40, \$9.91 and \$4.57, respectively. The values were estimated on the date of grant using the Black-Scholes option-pricing model. The following weighted-average assumptions were used in the model:

	2001	2000	1999
Risk-free interest rate	4.5%	6.5%	4.9%
Expected dividend yield	1.0%	2.0%	2.0%
Expected lives	4.0 years	3.7 years	5.5 years
Expected stock volatility	50%	46%	27%

As previously discussed, in April 1999, the Company's stockholders approved the 1998 Employee Stock Purchase Plan, whereby participating employees currently have the right to purchase common stock at a price equal to 85% of the lower of the closing price on the first day or the last day of the six-month offering period. The number of shares which an employee may purchase, subject to certain aggregate limits, is determined by the employee's voluntary contribution, which may not exceed 10% of base compensation. During 2001, the Company issued 242,120 shares under this plan at a weighted-average price of \$23.40 per share. During 2000, the Company issued 420,288 shares under this plan at a weighted-average price of \$21.84 per share. During 1999, the Company issued 716,000 shares under this plan at a weighted-average price of \$11.07 per share. There remains available for sale to employees an aggregate of 3.6 million shares of the Company's stock out of 5 million shares authorized by the stockholders.

# Notes to Financial Statements

continued

As permitted by SFAS No. 123, *Accounting for Stock-Based Compensation*, the Company continues to apply APB Opinion No. 25 in accounting for its stock option and stock purchase plans. As required, the following table discloses pro forma net income and diluted earnings per share had compensation cost for the Company's stock-based compensation plans been determined based on the fair value approach:

<i>(In thousands except per share data)</i>	2001	2000	1999
Net income:			
As reported	\$34,505	\$90,520	\$154,316
Pro forma	770	76,092	145,354
Diluted earnings per share			
As reported	0.33	0.89	1.66
Pro forma	0.01	0.76	1.56

Pro forma compensation cost may not be representative of that to be expected in future years since the estimated fair value of stock options is amortized to expense over the vesting period, and additional options may be granted in future years.

**Shareholder Rights Plan:** Under a Shareholder Rights Plan, preferred stock purchase rights were distributed on February 8, 1995 as a dividend at the rate of one right for each share of common stock outstanding. Each right, when exercisable, entitles a stockholder to purchase one one-thousandth of a share of a new series of junior participating preferred stock at a price of \$30. The rights become exercisable only if a person or group acquires 20% or more or announces a tender or exchange offer for 30% or more of the Company's common stock. This preferred stock is nonredeemable and will have 1,000 votes per share. The rights are nonvoting, expire in 2005 and may be redeemed prior to becoming exercisable. The Company has reserved 70,000 shares of preferred stock, designated as Series C Junior Participating Preferred Stock, for issuance upon exercise of such rights. If a person (an Acquiring Person) acquires or obtains the right to acquire 20% or more of the Company's outstanding common stock (other than pursuant to certain approved offers), each right (other than rights held by the Acquiring Person) will entitle the holder to purchase shares of common stock of the Company at one-half of the current market price at the date of occurrence of the event. In addition, in the event that the Company is involved in a merger or other business combination in which it is not the surviving corporation or in connection with which the Company's common stock is changed or converted, or it sells or transfers 50% or more of its assets or earning power to another person, each right that has not previously been exercised will entitle its holder to purchase shares of common stock of such other person at one-half of the current market price of such common stock at the date of the occurrence of the event.

**Comprehensive Income:** The components of accumulated other comprehensive income (loss) were as follows:

<i>(In thousands)</i>	Foreign Currency Translation Adjustments	Unrealized Gains on Derivative Instruments	Unrealized Gains (Losses) on Securities	Accumulated Other Comprehensive Income (Loss)
Balance, January 3, 1999	\$ 3,343	\$ —	\$ 386	\$ 3,729
Current year change	(17,804)	—	35	(17,769)
Balance, January 2, 2000	(14,461)	—	421	(14,040)
Current year change	(25,484)	—	482	(25,002)
Balance, December 31, 2000	(39,945)	—	903	(39,042)
Current year change	\$(20,976)	\$1,407	\$(2,329)	\$(21,898)
Balance, December 30, 2001	\$(60,921)	\$1,407	\$(1,426)	\$(60,940)

The tax effects related to each component of other comprehensive income (loss) were as follows:

<i>(In thousands)</i>	Before-Tax Amount	Tax (Provision) Benefit	After-Tax Amount
<b>2001</b>			
Foreign currency translation adjustments	\$(20,976)	\$ —	\$(20,976)
Unrealized gains on derivative instruments	1,407	—	1,407
Unrealized gains (losses) on securities:			
Losses arising during the period	(3,709)	1,271	(2,438)
Reclassification adjustment	167	(58)	109
Net unrealized losses on securities	(3,542)	1,213	(2,329)
Other comprehensive income (loss)	\$(23,111)	\$ 1,213	\$(21,898)
<b>2000</b>			
Foreign currency translation adjustments	\$(25,484)	\$ —	\$(25,484)
Unrealized gains on securities:			
Gains arising during the period	673	(192)	481
Reclassification adjustment	1	—	1
Net unrealized gains	674	(192)	482
Other comprehensive income (loss)	\$(24,810)	\$ (192)	\$(25,002)
<b>1999</b>			
Foreign currency translation adjustments	\$(17,804)	\$ —	\$(17,804)
Unrealized gains on securities:			
Gains arising during the period	143	(50)	93
Reclassification adjustment	(89)	31	(58)
Net unrealized gains	54	(19)	35
Other comprehensive income (loss)	\$(17,750)	\$ (19)	\$(17,769)

## Note 20: Financial Instruments

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments and accounts receivable. The Company believes it had no significant concentrations of credit risk as of December 30, 2001.

In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, generally have maturities that do not exceed 12 months, have no cash requirements until maturity and are recorded at fair value on the consolidated balance sheet. Credit risk and market risk are minimal as the foreign exchange instruments are contracted with major banking institutions. Gains and losses on the Company's foreign currency contracts are recognized immediately in earnings for hedges designated as fair value and, for hedges designated as cash flow, the related unrealized gains or losses are deferred as a component of other comprehensive income in the accompanying consolidated balance sheet. These deferred gains and losses are recognized in income in the period in which the underlying anticipated transaction occurs. Effectiveness of these cash flow hedges is measured utilizing the

# Notes to Financial Statements

continued

cumulative dollar offset method and is reviewed quarterly. For the year ended December 30, 2001, net losses from hedges reclassified from other comprehensive income to revenue and expense totaled \$36,000. The notional amount of the outstanding foreign currency contracts was approximately \$280 million as of December 30, 2001 and \$190 million at December 31, 2000. At December 30, 2001, the approximate fair value for foreign currency derivative instruments designated as fair value hedges was \$560,000 and at December 31, 2000 was not significant. The approximate fair value for foreign currency derivative instruments designated as cash flow hedges was \$380,000 and is recorded in other current assets with the offset to other comprehensive income. This gain will be recognized in earnings over the next 12 months.

## Note 21: Leases

The Company leases certain property and equipment under operating leases. Rental expense charged to continuing operations for 2001, 2000 and 1999 amounted to \$19.6 million, \$17.2 million and \$18.1 million, respectively. Minimum rental commitments under noncancelable operating leases are as follows: \$20.0 million in 2002, \$17.4 million in 2003, \$15.4 million in 2004, \$12.1 million in 2005, \$12.8 million in 2006 and \$115.0 million after 2006.

Rental expenses charged to discontinued operations for 2001, 2000 and 1999 amounted to \$3.4 million, \$1.8 million and \$1.1 million, respectively. Minimum rental commitments under noncancelable operating leases are as follows: \$4.8 million in 2002, \$4.1 million in 2003, \$3.6 million in 2004, \$3.5 million in 2005, \$2.4 million in 2006 and \$22.3 million after 2006.

## Note 22: Industry Segment and Geographic Area Information

In 1998, the Company adopted SFAS No. 131, *Disclosures about Segments of an Enterprise and Related Information*, which changed the way the Company reports information about its operating segments. The Company's businesses are reported as three reportable segments which reflect the Company's management and structure under three strategic business units ("SBU's"). The accounting policies of the reportable segments are the same as those described in Note 1. The Company evaluates the performance of its operating segments based on operating profit. Intersegment sales and transfers are not significant.

The operating segments and their principal products and services are:

**Life Sciences:** Sample handling and measuring instruments, computer software and chemical reagents for use in bio-screening and population screening laboratories. Bio-screening activities include academic research applications and drug discovery applications in high throughput screening laboratories of major pharmaceutical companies. Population screening activities include inherited and infectious disease screening, as well as routine clinical diagnostics.

**Optoelectronics:** A broad spectrum of optoelectronic products, including large area amorphous silicon detectors, high volume and high-performance specialty lighting sources, detectors, imaging devices, as well as telecom products, which include emitters, receivers and mux arrays.

**Analytical Instruments:** Products and services for measurement and testing applications, including analytical instruments for the pharmaceutical, food and beverage, environmental, chemical and plastics industries.

Sales and operating profit by segment for the three years ended December 30, 2001 are shown in the table below:

<i>(In thousands)</i>	2001	2000	1999
<b>Life Sciences</b>			
Sales	\$ 346,109	\$ 221,401	\$ 158,009
Operating (loss) profit	(45,957)	(3,636)	15,768
<b>Optoelectronics</b>			
Sales	415,745	496,851	447,681
Operating profit	45,776	96,931	40,317
<b>Analytical Instruments</b>			
Sales	568,200	617,280	445,145
Operating profit (loss)	78,420	56,897	(21,400)
<b>Other</b>			
Sales	—	—	—
Operating (loss)	(14,290)	(17,523)	(8,181)
<b>Continuing Operations</b>			
Sales	\$1,330,054	\$1,335,532	\$1,050,835
Operating profit	\$ 63,949	\$ 132,669	\$ 26,504

The Company's Technical Services segment, former Department of Energy segment, Detection and Security Systems business (formerly included in the Analytical Instruments segment) and Fluid Sciences segment are presented as discontinued operations and, therefore, are not included in the preceding table.

Additional information relating to the Company's operating segments is as follows:

<i>(In thousands)</i>	Depreciation and Amortization Expense			Capital Expenditures		
	2001	2000	1999	2001	2000	1999
Life Sciences	\$34,885	\$17,719	\$ 6,189	\$17,691	\$16,239	\$ 7,465
Optoelectronics	26,245	25,967	34,430	31,433	34,242	21,155
Instruments	17,952	21,172	17,019	32,295	3,881	4,818
Other	1,415	859	1,111	7,280	956	1,402
Continuing operations	\$80,497	\$65,717	\$58,749	88,699	\$55,318	\$34,840
Discontinued operations	\$13,710	\$13,431	\$ 8,207	\$13,017	\$15,280	\$ 7,593

# Notes to Financial Statements

continued

<i>(In thousands)</i>	Total Assets	
	2001	2000
Life Sciences	\$1,051,667	\$ 600,168
Optoelectronics	504,670	512,395
Instruments	590,452	720,195
Other (including net assets of discontinued operations)	772,340	355,575
	<b>\$2,919,129</b>	<b>\$2,188,333</b>

The following geographic area information for continuing operations includes sales based on location of external customer and net property, plant and equipment based on physical location:

<i>(In thousands)</i>	Sales		
	2001	2000	1999
U.S.	\$ 581,121	\$ 551,264	\$ 453,497
United Kingdom	85,990	86,081	48,067
Germany	86,192	92,926	90,604
Japan	83,778	75,986	71,685
France	45,123	41,097	26,739
Italy	49,068	50,228	49,496
Other Non-U.S.	398,782	437,950	310,747
	<b>\$1,330,054</b>	<b>\$1,335,532</b>	<b>\$1,050,835</b>

<i>(In thousands)</i>	Net Property, Plant and Equipment	
	2001	2000
U.S.	\$151,536	\$126,414
Canada	33,876	19,051
Singapore	15,600	12,002
United Kingdom	14,498	12,376
Germany	9,108	14,137
Finland	6,953	26,356
Other non-U.S.	29,961	26,430
	<b>\$261,532</b>	<b>\$236,766</b>

## Note 23: Quarterly Financial Information (Unaudited)

Selected quarterly financial information follows:

<i>(in thousands except per share data)</i>	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Year
<b>2001</b>					
Sales	\$334,899	\$331,806	\$302,131	\$361,218	\$1,330,054
Operating income (loss) from continuing operations	32,651	35,451	33,300	(37,453)	63,949
Income (loss) from continuing operations before income taxes	20,772	28,252	28,910	(43,780)	34,154
Income (loss) from continuing operations	13,028	19,955	21,611	(55,215)	(620)
Net income (loss)	23,496	29,409	31,219	(49,619)	34,505
Basic earnings (loss) per share:					
Continuing operations	0.13	0.20	0.21	(0.49)	(0.01)
Net income (loss)	0.23	0.29	0.31	(0.44)	0.33
Diluted earnings (loss) per share:					
Continuing operations	0.13	0.19	0.21	(0.49)	(0.01)
Net income (loss)	0.23	0.28	0.30	(0.44)	0.33
Cash dividends per common share	0.07	0.07	0.07	0.07	0.28
Market price of common stock:					
High	52.31	38.27	34.06	35.95	52.31
Low	21.50	21.28	24.90	25.27	21.28
Close	26.23	27.53	26.24	35.74	35.74
<b>2000</b>					
Sales	\$311,752	\$309,169	\$340,140	\$374,471	\$1,335,532
Operating income from continuing operations	31,373	36,973	9,005	55,318	132,669
Income (loss) from continuing operations before income taxes	25,141	30,811	(2,552)	45,577	98,977
Income (loss) from continuing operations	17,396	22,654	(10,275)	29,503	59,278
Net income	16,243	35,573	2,080	36,624	90,520
Basic earnings (loss) per share:					
Continuing operations	0.18	0.23	(0.10)	0.30	0.60
Net income	0.17	0.36	0.02	0.37	0.92
Diluted earnings (loss) per share:					
Continuing operations	0.17	0.22	(0.10)	0.28	0.58
Net income	0.16	0.35	0.02	0.35	0.89
Cash dividends per common share	0.07	0.07	0.07	0.07	0.28
Market price of common stock:					
High	39.63	34.38	53.50	59.57	59.57
Low	19.53	25.00	31.07	44.53	19.53
Close	33.25	33.07	52.19	52.50	52.50

## Report of Independent Public Accountants

### To the Stockholders of PerkinElmer, Inc.:

We have audited the accompanying consolidated balance sheets of PerkinElmer, Inc. (a Massachusetts corporation) and subsidiaries as of December 30, 2001 and December 31, 2000 and the related consolidated statements of income, stockholders' equity and cash flows for the years ended December 30, 2001, December 31, 2000 and January 2, 2000. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of PerkinElmer, Inc. and subsidiaries as of December 30, 2001 and December 31, 2000, and the results of their operations and their cash flows for the years ended December 30, 2001, December 31, 2000 and January 2, 2000 in conformity with accounting principles generally accepted in the United States.



**Arthur Andersen LLP**

Boston, Massachusetts

January 24, 2002 (except with respect to matters discussed in Note 14 for which the date is March 1, 2002)

### Corporate Headquarters

PerkinElmer, Inc.  
45 William Street  
Wellesley, MA 02481-4078  
Phone: (781) 237-5100  
Fax: (781) 237-9386  
www.perkinelmer.com

Information requests from security analysts and other members of the financial community can be directed to Investor Relations.

### Annual Meeting

The Annual Meeting of PerkinElmer, Inc. stockholders will be held at 10:30 A.M. on Tuesday, April 23, 2002, at the Sheraton Needham Hotel in Needham, Massachusetts. A formal meeting notice, an Annual Report, Proxy Statement and form of Proxy, will be mailed to each stockholder of record.

### Independent Accountants

Arthur Andersen LLP  
225 Franklin Street  
Boston, MA 02110

### Stockholder Services

PerkinElmer stockholder records are maintained by its transfer agent, Mellon Investor Services, LLC. Inquiries relating to stockholder records, stock transfer, changes of ownership, changes of address, dividend payments, dividend reinvestment, direct deposit of quarterly dividends and consolidation of accounts should be addressed to:

Mellon Investor Services, LLC  
85 Challenger Road  
Ridgefield Park, NJ 07660  
www.melloninvestor.com

Or stockholders may call Mellon toll-free at 1-877-711-4098. For the hearing-impaired, call 1-800-231-5469 (domestic), 1-201-329-8354 (foreign), (TTY/TDD).

### Form 10-K and Other Reports

Upon request, PerkinElmer, Inc. will provide a copy of its Annual Report, Form 10-K (filed with the Securities and Exchange Commission) and Investor Information. Call 1-877-PKI-NYSE.

### Stock Exchange Information

PerkinElmer, Inc. common stock is listed and traded on the New York Stock Exchange. Ticker symbol: PKI.

### Trading Information

Common Stock Market Price

	2001		2000	
	High	Low	High	Low
4th Quarter	\$ 35.74	\$ 25.72	\$ 59.75	\$ 44.53
3rd Quarter	\$ 33.95	\$ 25.06	\$ 53.50	\$ 31.06
2nd Quarter	\$ 37.56	\$ 21.38	\$ 34.38	\$ 25.00
1st Quarter	\$ 50.03	\$ 22.33	\$ 39.63	\$ 19.53

### Stockholder Information Line

The Company's quarterly earnings results are available through the PerkinElmer Stockholder Information Line. Stockholders can receive current corporate information, such as dividend data, recent earnings and press release information. The toll-free number is 1-877-PKI-NYSE.

### Comparability; Computations of Earnings

As a result of significant changes in the Company's portfolio during recent years, period over period results are frequently not comparable. Certain references throughout the text of this document to revenue, operating margins, net income and earnings per share are on a continuing operations basis and exclude the amortization of goodwill and intangible assets, and nonrecurring items. Nonrecurring items represent income and expenses associated with an acquisition, restructuring, divestiture or other unusual event that are not expected to have an impact on ongoing operations.

### Factors Affecting Future Performance

This document contains "forward-looking" statements. For this purpose, any statements contained in this document that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this document. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: our ability to successfully integrate Packard BioScience's operations and employees with ours; our ability to realize anticipated synergies and cost savings from the Packard BioScience transaction; our inability to consummate a disposition of the Fluid Sciences business on favorable terms; a downturn in our customers' markets or in general economic conditions; our failure to introduce new products in a timely manner; economic, political and other risks associated with international sales and operations; difficulties integrating technologies, operations and personnel of recent acquisitions; competition from third parties, including pricing pressure; governmental regulation; and our level of debt and the possible incurrence of additional debt in the future. These and other important factors that may affect our actual results are discussed in detail in the risk factors set forth in Amendment No. 1 to our Registration Statement on Form S-4, filed on August 17, 2001 with the Securities and Exchange Commission, under the captions "Risk Factors – Risks Relating to the Merger" and "Risk Factors – Risks Relating to PerkinElmer's Business," which discussion is expressly incorporated by reference in this document.

*Six Sigma® is a registered trademark of Motorola, Inc. Elan® is a registered trademark of MDS Sciex. Unless otherwise noted, all other trademarks and service marks are the property of PerkinElmer, Inc.*



PerkinElmer, Inc.

45 William Street Wellesley, MA 02481 Phone: 781-237-5100 Fax: 781-237-9386 [www.perkinelmer.com](http://www.perkinelmer.com)